Disease overview

Alterations

138

Molecular (A)

100

Clinical (B–E)

Direct drugs

196

Via biomarker

Natural agents

Natural products

Merged ranked

249

With trial/literature evidence

Sources: Seeds, Open Targets, HPO, ClinicalTrials.gov, DGIdb, ChEMBL, PubMed MeSH, PubMed Literature · Pipeline phase 7 · Updated 2026-07-05

Remission & chronicity

Spontaneous remission

Spontaneous elite control (natural viremic suppression without ART) in <1% of people living with HIV; untreated, median time to AIDS ~10 years; viral rebound within weeks of ART interruption in 99%+ of patients

Best-intervention remission

Modern ART (integrase inhibitor-based): viral suppression to undetectable in >95% within 6 months, maintained indefinitely on treatment; life expectancy near-normalised with early treatment; 7 documented sterilising cures worldwide (all via CCR5-Δ32 stem cell transplantation); post-treatment controllers (VISCONTI cohort): ~5-15% of early-treated individuals achieve durable ART-free viremic suppression

Drug-free remission

—

Relapse after remission

—

Chronicity

—

Gap size

Very large (sterilising cure); near-zero biological gap for quality-of-life control on ART; large access gap globally

Primary barrier

biological (sterilising cure) + access (ART, particularly in LMIC)

Barrier detail: ART is the most successful chronic disease management story in medicine but is definitionally not a cure; 39 million people living with HIV globally, only 77% on ART, only 72% virally suppressed (2023 UNAIDS); broadly neutralising antibodies (bNAbs) showing promising functional remission signals (ACTG A5386, 2025)

Last SoC change: 2022-2023 — long-acting injectables (cabotegravir + rilpivirine every 2 months, lenacapavir every 6 months) transformed adherence paradigm; dolutegravir-based regimens as first-line since 2018; ART inception for all regardless of CD4 count since 2015 (START trial); first drug (AZT) 1987

Remission data layers: disease_db_100 · source-locked manual data · confidence: high

Identifiers: MONDO: MONDO:0005109 · EFO: EFO_0000180 · MESH: D015658 · UMLS_CUI: C0276529

Alterations

138 total · Types A (molecular) through E (functional)

Name	Type	Subtype	Direction	Frequency	Evidence	Sources	Links
Abnormal gonadotropin-releasing hormone concentration	Lab / Clinical	Lab value	—	—	Moderate	HPO, Monarch	HPO
Anorexia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Cachexia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Immunodeficiency	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Malabsorption	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Malnutrition	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Skeletal muscle atrophy	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Weight loss	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
AP2A1 adaptor related protein complex 2 subunit alpha 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AP2A2 adaptor related protein complex 2 subunit alpha 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AP2B1 adaptor related protein complex 2 subunit beta 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AP2M1 adaptor related protein complex 2 subunit mu 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AP2S1 adaptor related protein complex 2 subunit sigma 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
APOBEC3G apolipoprotein B mRNA editing enzyme catalytic subunit 3G	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ATP6V1H ATPase H+ transporting V1 subunit H	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Any Condomless Anal Sex Acts	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Any Pre-Exposure Prophylaxis (PrEP) Use	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Average graft function as assessed by ALT	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Average graft function as assessed by AST	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Average graft function as assessed by bilirubin	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
BANF1 barrier to autointegration nuclear assembly factor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CCNH cyclin H	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CCNK cyclin K	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CCNT1 cyclin T1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CCNT2 cyclin T2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CCR5 C-C motif chemokine receptor 5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CD4 CD4 molecule	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDK7 cyclin dependent kinase 7	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDK9 cyclin dependent kinase 9	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CTDP1 CTD phosphatase subunit 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CXCR4 C-X-C motif chemokine receptor 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CYP3A4 cytochrome P450 family 3 subfamily A member 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CYP3A43 cytochrome P450 family 3 subfamily A member 43	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CYP3A5 cytochrome P450 family 3 subfamily A member 5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CYP3A7 cytochrome P450 family 3 subfamily A member 7	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Change From Baseline in Cell-associated HIV-1 RNA Levels in PBMCs in Cohort 4	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Change From Baseline in Cellular Markers of Immune Activation (CD38/HLA-DR Expression on CD4+ T-cells) in Cohort 4	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Change From Baseline in Cellular Markers of Immune Activation (CD38/HLA-DR Expression on CD4+ T-cells) in Cohorts 1-3	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Change From Baseline in PTEF-b Phosphorylation (pNFKB+%) in CD4+ T-cells in Cohort 4	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Change From Baseline in Plasma HIV-1 RNA Levels as Detected by Single Copy Assay in Cohort 4	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Change From Baseline in Plasma HIV-1 RNA Levels as Detected by Single Copy Assay in Cohorts 1-3	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Decisional Balance	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Depression: BSI GSI	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
Depression: HAM-D	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
ELL elongation factor for RNA polymerase II	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ELOA elongin A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ELOA2 elongin A2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ELOB elongin B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ELOC elongin C	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ERCC2 ERCC excision repair 2, TFIIH core complex helicase subunit	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ERCC3 ERCC excision repair 3, TFIIH core complex helicase subunit	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GTF2A1 general transcription factor IIA subunit 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GTF2A2 general transcription factor IIA subunit 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GTF2B general transcription factor IIB	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GTF2E1 general transcription factor IIE subunit 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GTF2E2 general transcription factor IIE subunit 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GTF2F1 general transcription factor IIF subunit 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GTF2F2 general transcription factor IIF subunit 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GTF2H1 general transcription factor IIH subunit 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GTF2H2 general transcription factor IIH subunit 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GTF2H3 general transcription factor IIH subunit 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GTF2H4 general transcription factor IIH subunit 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GTF2H5 general transcription factor IIH subunit 5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Graft function as assessed by AST to Platelet Ratio (APRI) index	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
Graft function as assessed by Fibrosis-4 index	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
Graft function as assessed by Mean calculated MELD score	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
Graft function as assessed by liver stiffness	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
HMGA1 high mobility group AT-hook 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KPNB1 karyopherin subunit beta 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MNAT1 MNAT1 component of CDK activating kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Metabolic Outcome as assessed by Body mass index (BMI)	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
Minority Stress: Brooding	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Minority Stress: DERS	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Minority Stress: GRRS	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Minority Stress: IHS	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Minority Stress: Rathus Assertiveness Schedule	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Minority Stress: SOCS	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
NCBP1 nuclear cap binding protein subunit 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NCBP2 nuclear cap binding protein subunit 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NELFA negative elongation factor complex member A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NELFB negative elongation factor complex member B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NELFCD negative elongation factor complex member C/D	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NELFE negative elongation factor complex member E	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NUP153 nucleoporin 153	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NUP160 nucleoporin 160	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NUP210 nucleoporin 210	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NUP35 nucleoporin 35	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NUP98 nucleoporin 98 and 96 precursor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
POLR2A RNA polymerase II subunit A	Molecular	Gene	—	—	Emerging	Open Targets	Ensembl Open Targets
POLR2B RNA polymerase II subunit B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
POLR2C RNA polymerase II subunit C	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
POLR2D RNA polymerase II subunit D	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
POLR2E RNA polymerase II, I and III subunit E	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
POLR2F RNA polymerase II, I and III subunit F	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
POLR2G RNA polymerase II subunit G	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
POLR2H RNA polymerase II, I and III subunit H	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
POLR2I RNA polymerase II subunit I	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
POLR2J RNA polymerase II subunit J	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
POLR2K RNA polymerase II, I and III subunit K	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
POLR2L RNA polymerase II, I and III subunit L	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PPIA peptidylprolyl isomerase A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PSIP1 PC4 and SRSF1 interacting protein 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RAN RAN, member RAS oncogene family	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RANBP2 RAN binding protein 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RPS27A ribosomal protein S27a	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SSRP1 structure specific recognition protein 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SUPT16H SPT16 homolog, facilitates chromatin remodeling subunit	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SUPT4H1 SPT4 homolog, DSIF elongation factor subunit	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SUPT5H SPT5 homolog, DSIF elongation factor subunit	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Safer Sex Self-Efficacy	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Substance Use: SIP-AD	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
TAF1 TATA-box binding protein associated factor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TAF10 TATA-box binding protein associated factor 10	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TAF11 TATA-box binding protein associated factor 11	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TAF12 TATA-box binding protein associated factor 12	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TAF13 TATA-box binding protein associated factor 13	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TAF15 TATA-box binding protein associated factor 15	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TAF1L TATA-box binding protein associated factor 1 like	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TAF2 TATA-box binding protein associated factor 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TAF3 TATA-box binding protein associated factor 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TAF4 TATA-box binding protein associated factor 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TAF4B TATA-box binding protein associated factor 4b	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TAF5 TATA-box binding protein associated factor 5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TAF6 TATA-box binding protein associated factor 6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TAF7 TATA-box binding protein associated factor 7	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TAF7L TATA-box binding protein associated factor 7 like	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TAF8 TATA-box binding protein associated factor 8	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TAF9 TATA-box binding protein associated factor 9	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TAF9B TATA-box binding protein associated factor 9b	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TBP TATA-box binding protein	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TCEA1 transcription elongation factor A1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
To compare interest in or use of HIV prevention services between intervention and control groups	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
To evaluate the feasibility and acceptability of a barbershop based HIV prevention initiative	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
To evaluate the preliminary effectiveness of the intervention on change in risk behaviors associated with HIV acquisition	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
UBA52 ubiquitin A-52 residue ribosomal protein fusion product 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
UBB ubiquitin B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
UBC ubiquitin C	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
XPO1 exportin 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets

Therapeutics

Direct disease associations, biomarker-linked drugs, OSMF narrative-review natural agents, merged ranking, and clinical trial / literature evidence (top agents)

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
ABACAVIR SULFATE	Small molecule	Approved	Strong	100	8 trials 2 Trial pubs 2 RCT View evidence Registry trials NCT00087945 — Blood Levels of Abacavir in HIV Infected Adolescents (COMPLETED) NA NCT00978237 — Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients (COMPLETED) PHASE4 NCT00433992 — Metabolic Effects of Non-Thymidine Analogue Anti-HIV Medications (COMPLETED) NCT00001086 — A Study of Abacavir Plus Indinavir Sulfate Plus Efavirenz in HIV-Infected Patients (COMPLETED) PHASE2 NCT03760458 — The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age (COMPLETED) PHASE1, PHASE2 NCT00427297 — Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya (TERMINATED) PHASE3 NCT04155554 — Neurological Monitoring in Patients Switching From Dolutegravir Based Regimen to Bictegravir Based Regimen (UNKNOWN) PHASE3 NCT02708342 — Observational, Retrospective Analysis in HIV-1 Infected Patients. (ORASWIRAL) (COMPLETED) Published literature Clinical trial publication Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials (The lancet. HIV, 2024) Clinical trial publication Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment (AIDS (London, England), 2009) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
AMPRENAVIR	Small molecule	Approved	Strong	100	8 trials 1 Meta-analysis 77 Trial pubs 39 RCT View evidence Registry trials NCT00089583 — 48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection (COMPLETED) PHASE2 NCT00006591 — Ritonavir and Agenerase Treatment for Patients Who Have Failed Previous Anti-HIV Treatment (UNKNOWN) NA NCT00148785 — A Pharmacokinetic (PK) Study of a Combination of Indinavir, Ritonavir, and Amprenavir (COMPLETED) PHASE4 NCT00192660 — HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001) (COMPLETED) PHASE4 NCT00056641 — Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients (COMPLETED) PHASE2 NCT01054638 — HIV Treatment and CVD Events (COMPLETED) NCT00071760 — Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects (COMPLETED) PHASE2 NCT00001766 — Drug Interactions Among Anti-HIV Agents (COMPLETED) PHASE1 Published literature Meta-analysis Interactions of Antiretroviral Drugs with Food, Beverages, Dietary Supplements, and Alcohol: A Systematic Review and Meta-analyses (AIDS and behavior, 2023) Clinical trial publication Fosamprenavir with Ritonavir Pharmacokinetics during Pregnancy (Antimicrobial agents and chemotherapy, 2020) Clinical trial publication Population pharmacokinetic modeling and simulation of amprenavir following fosamprenavir/ritonavir administration for dose optimization in HIV infected pediatric patients (Journal of clinical pharmacology, 2014) Clinical trial publication Long-term safety study of fosamprenavir-containing regimens in HIV-1-infected patients (HIV clinical trials, 2013) Clinical trial publication Pharmacokinetics and 48-week safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2- to 18-year-old children (The Pediatric infectious disease journal, 2014) Clinical trial publication Pharmacokinetics, safety and antiviral activity of fosamprenavir/ritonavir-containing regimens in HIV-infected children aged 4 weeks to 2 years-48-week study data (The Pediatric infectious disease journal, 2014) Randomized controlled trial Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146 (Therapeutic drug monitoring, 2013) Randomized controlled trial Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers (HIV medicine, 2010) Randomized controlled trial Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance (The Journal of antimicrobial chemotherapy, 2009) Randomized controlled trial Effect of baseline viral susceptibility on response to darunavir/ritonavir versus control protease inhibitors in treatment-experienced HIV type 1-infected patients: POWER 1 and 2 (AIDS research and human retroviruses, 2008) Randomized controlled trial Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen (Antimicrobial agents and chemotherapy, 2008) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
ATAZANAVIR SULFATE	Small molecule	Approved	Strong	100	8 trials View evidence Registry trials NCT00357721 — Atazanavir Twice Daily (COMPLETED) PHASE1 NCT01232127 — Effects of Famotidine on the Pharmacokinetics of Atazanavir When Coadministered to Participants With HIV Infection (COMPLETED) PHASE4 NCT03708861 — Pharmacokinetics of Maraviroc and Boosted Atazanavir Dual Regimen in Stable HIV-infected Patients (WITHDRAWN) PHASE3 NCT01805427 — Antiretroviral Therapy and Extreme Weight (COMPLETED) NCT01691794 — Safety Sudy of Atazanavir Boosted With Ritonavir in the Treatment of HIV Infection in Pediatric Patients (COMPLETED) PHASE4 NCT00135356 — Study of Reyataz in HIV-infected Patients With Lipodystrophy Syndrome (COMPLETED) PHASE4 NCT02302547 — Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (COMPLETED) PHASE3 NCT00192608 — A 48-Week, Randomised, Study to Describe the Pharmacokinetic Profile and Durability of Atazanavir-Saquinavir-Ritonavir Once Daily and Describe the Pharmacokinetic Profile of Saquinavir-Ritonavir Using Saquinavir 500mg Formulation: the ASK-500 Study (COMPLETED) NA CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
CABOTEGRAVIR	Small molecule	Approved	Strong	100	8 trials 10 Cochrane 11 Meta-analysis 75 Trial pubs 47 RCT View evidence Registry trials NCT05152953 — Preparing for Pharmacy-based Delivery of Long-acting Injectable Antiretroviral Therapy (LAI-ART) (COMPLETED) NCT06565013 — Chemsex Health Evaluation With Extended Release System for HIV Treatment (NOT_YET_RECRUITING) NCT06145854 — Cisgender Female Patients Who Start on Long Acting Cabotegravir for PrEP (ACTIVE_NOT_RECRUITING) NCT04542070 — A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed (COMPLETED) PHASE3 NCT05949203 — Oregon PrEP at Home Study (UNKNOWN) NCT05986084 — Tshireletso: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Population in Botswana (ACTIVE_NOT_RECRUITING) PHASE4 NCT03635788 — The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE (ACTIVE_NOT_RECRUITING) PHASE3 NCT04484337 — Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants (COMPLETED) PHASE1 Published literature Cochrane review Lenacapavir as pre-exposure prophylaxis for HIV prevention (The Cochrane database of systematic reviews, 2026) Cochrane review The safety of cabotegravir in pregnancy: a systematic review and meta-analysis (BMC infectious diseases, 2025) Cochrane review Outcomes of real-world initiation of long-acting injectable cabotegravir and rilpivirine (LA-I CAB + RPV) in individuals with viraemia: A systematic review of baseline characteristics, virological failure outcomes and discontinuations (HIV medicine, 2026) Cochrane review Long-acting injectable cabotegravir and rilpivirine in observational cohort studies: A systematic review on virological failure, resistance and re-suppression outcomes in virally suppressed individuals living with HIV (HIV medicine, 2025) Cochrane review Comparison of treatment-emergent resistance-associated mutations and discontinuation due to adverse events among integrase strand transfer inhibitor-based single-tablet regimens and cabotegravir + rilpivirine for the treatment of virologically suppressed people with HIV: A systematic literature review and network meta-analysis (HIV medicine, 2025) Meta-analysis Rapid diagnostic tests, laboratory-based immunoassay and nucleic acid testing strategies for long-acting injectable pre-exposure prophylaxis: A systematic review and meta-analysis (PLoS medicine, 2026) Meta-analysis Cabotegravir Plus Rilpivirine Injection for Virally Suppressed Persons with HIV-1 infection: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (Clinical therapeutics, 2025) Systematic review High Virologic Suppression and Favorable Profiles of Two-Drug Antiretroviral Regimens in Africa: A Systematic Review of Current Evidence (Clinical pharmacology and therapeutics, 2025) Clinical trial publication Feasibility, Fidelity, and Effectiveness of Administering Long-Acting Cabotegravir + Rilpivirine in Infusion Centers in the United States: Findings From the Phase 4 GLACIER Implementation Study (Journal of the International Association of Providers of AIDS Care, 2026) Clinical trial publication Advancing youth HIV prevention and care in Uganda: stakeholder-informed innovations through implementation science, protocol for a randomized controlled trial (BMC health services research, 2026) Clinical trial publication Long-acting HIV pre-exposure prophylaxis integrated with community-based sexual and reproductive health services in South Africa (LAPIS): study protocol for a hybrid (1a) cluster randomised controlled phase 3B trial of effectiveness and implementation (BMC public health, 2026) Clinical trial publication Safety, antiviral activity, and pharmacokinetics of long-acting injectable cabotegravir-rilpivirine in virologically suppressed adolescents living with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multinational, phase 1/2, single-arm study (The lancet. HIV, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
CHEMBL3301594	Small molecule	Approved	Strong	100	—	ChEMBL	ChEMBL Open Targets
COBICISTAT	Small molecule	Approved	Strong	100	—	Open Targets, ChEMBL	ChEMBL Open Targets
DORAVIRINE	Small molecule	Approved	Strong	100	8 trials 2 Cochrane 3 Meta-analysis 34 Trial pubs 25 RCT View evidence Registry trials NCT05766501 — A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054) (ACTIVE_NOT_RECRUITING) PHASE3 NCT04665375 — Can INSTI-associated Weight Gain be Halted or Reversed With a Switch to Doravirine/Lamivudine/Tenofovir DF? (TERMINATED) PHASE4 NCT05477407 — Adipose Tissue After Switch to Doravirine (COMPLETED) NA NCT04233372 — Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo®) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study (COMPLETED) PHASE4 NCT03894124 — Pharmacokinetics of Plasma Doravirine Once Daily Over 72 Hours Following Drug Intake Cessation in Healthy Volunteers (COMPLETED) PHASE1 NCT05648201 — Study on PhArmacokinetics of First liNe Antiretrovirals in Healthy Breastfeeding Volunteers (COMPLETED) PHASE4 NCT06034938 — DOR/TDF/3TC Switch With M184V/I in People With Controlled HIV (Drive Off-Road) (RECRUITING) PHASE2 NCT01632345 — A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007) (COMPLETED) PHASE2 Published literature Cochrane review Efficacy and safety of doravirine/islatravir for HIV-1: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials (HIV research & clinical practice, 2026) Cochrane review Efficacy and safety of doravirine/islatravir for the treatment of HIV-1: a systematic review and meta-analysis of randomized controlled trials with GRADE assessment (European journal of clinical pharmacology, 2026) Meta-analysis Efficacy and safety of doravirine in treatment-naive HIV-1-infected adults: a systematic review and meta-analysis (Environmental science and pollution research international, 2021) Systematic review Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV: A Systematic Review (Clinical pharmacokinetics, 2023) Systematic review Clinical Impact of Virological Failure and Resistance Analysis Definitions used in Pivotal Clinical Trials of Initial Antiretroviral Treatment: A Systematic Review (AIDS reviews, 2018) Clinical trial publication Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial (The lancet. HIV, 2026) Clinical trial publication Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial (Lancet (London, England), 2026) Clinical trial publication Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial (Lancet (London, England), 2026) Clinical trial publication Doravirine Resistance Patterns Identified Through Week 192 in the DRIVE-FORWARD and DRIVE-AHEAD Phase 3 Clinical Trials (Journal of acquired immune deficiency syndromes (1999), 2026) Clinical trial publication Cardiovascular Risk Assessment Using the Atherosclerotic Cardiovascular Disease Risk Score Model after Continuing or Switching to a Doravirine-Based HIV Treatment Regimen (Journal of acquired immune deficiency syndromes (1999), 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
EFAVIRENZ	Small molecule	Approved	Strong	100	8 trials 26 Cochrane 61 Meta-analysis 819 Trial pubs 559 RCT View evidence Registry trials NCT03158857 — Hepatitis C Treatment Study in Myanmar (WITHDRAWN) NCT03502005 — Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1 (COMPLETED) PHASE4 NCT00978237 — Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients (COMPLETED) PHASE4 NCT01065792 — Stocrin Re-examination Study (0831-028) (COMPLETED) NCT01075152 — Cryptococcal Optimal ART Timing Trial (COMPLETED) PHASE4 NCT00001086 — A Study of Abacavir Plus Indinavir Sulfate Plus Efavirenz in HIV-Infected Patients (COMPLETED) PHASE2 NCT00427297 — Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya (TERMINATED) PHASE3 NCT01778413 — Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine (COMPLETED) PHASE4 Published literature Cochrane review Effectiveness of interventions on cognitive decline risk for people living with HIV on antiretroviral therapy: a systematic review (The lancet. Healthy longevity, 2026) Cochrane review Virological outcomes of dolutegravir-based versus other antiretroviral regimens in people living with HIV: A systematic review and meta-analysis (BMC infectious diseases, 2026) Cochrane review Insights from systematic reviews (2019-2024) and drug interaction database analysis in people with HIV and comorbidities (International journal of STD & AIDS, 2026) Cochrane review Efficacy of artemisinin-based combination therapy (ACT) in people living with HIV (PLHIV) diagnosed with uncomplicated Plasmodium falciparum malaria in Africa: a WWARN systematic review (Malaria journal, 2025) Cochrane review Cardiovascular disease and its risk factors among people living with HIV: A systematic review and meta-analysis (Journal of infection and public health, 2025) Meta-analysis Self-reported sleep disturbances among people living with HIV in China: A Systematic Review and Meta-Analysis (Behavioral sleep medicine, 2025) Meta-analysis Risk of viral failure after simplification therapy without using integrase inhibitors compared with maintenance of triple antiretroviral therapy: A systematic review and meta-analysis (The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2024) Meta-analysis Adverse perinatal outcomes associated with different classes of antiretroviral drugs in pregnant women with HIV (AIDS (London, England), 2025) Clinical trial publication Comparative evaluation of human T lymphocytes in HIV patients treated with lamivudine + zidovudine combined with nevirapine versus efavirenz (Medicine, 2026) Clinical trial publication Brain Structure of South African Children Born to Mothers on Dolutegravir Versus Efavirenz-Based Antiretroviral Therapy (Journal of the Pediatric Infectious Diseases Society, 2026) Clinical trial publication Initiation of dolutegravir vs efavirenz on 12- and 24-month weight, body mass index, blood pressure, and incident hypertension: A target trial emulation (Annals of epidemiology, 2026) Clinical trial publication HIV drug resistance amongst children and adolescents with viraemia in Lesotho and Tanzania: a nested analysis in the GIVE MOVE trial (The Journal of antimicrobial chemotherapy, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
ELVITEGRAVIR	Small molecule	Approved	Strong	100	8 trials 3 Cochrane 11 Meta-analysis 71 Trial pubs 50 RCT View evidence Registry trials NCT02302547 — Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (COMPLETED) PHASE3 NCT01694420 — Treatment of Acute HIV Infection With Quad Fixed-dose Combination (FDC) Tablet (COMPLETED) PHASE3 NCT00298350 — Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART. (COMPLETED) PHASE2 NCT00869557 — Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults (COMPLETED) PHASE2 NCT02306577 — STRIBILD in Non-Nucleoside Resistant Patients (SINNR STUDY) (UNKNOWN) NCT02351908 — Renal Integrase Study (COMPLETED) PHASE4 NCT02198443 — Comparison of Two Combinations in Antiretroviral Post-Exposure Prophylaxis for HIV-1: Tenofovir/Emtricitabine (Truvada ®) + Lopinavir/Ritonavir (Kaletra ®) vs Tenofovir/Emtricitabine/Cobicistat/Elvitegravir (Stribild ®). Prospective, Randomized, Open. (COMPLETED) PHASE4 NCT03205696 — Prevention and Treatment Continuum for Youth at HIV Risk, Acutely Infected and With Established HIV Infection (COMPLETED) Published literature Cochrane review Deep sequencing reveals underestimated burden of integrase inhibitor resistance mutations in people living with HIV: a global individual patient data meta-analysis (Emerging microbes & infections, 2025) Cochrane review Effects of different integrase strand transfer inhibitors on body weight in patients with HIV/AIDS: a network meta-analysis (BMC infectious diseases, 2022) Cochrane review Therapy-Emergent Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Patients: A Subgroup Meta-Analysis of Clinical Trials (PloS one, 2016) Meta-analysis Interactions of Antiretroviral Drugs with Food, Beverages, Dietary Supplements, and Alcohol: A Systematic Review and Meta-analyses (AIDS and behavior, 2023) Meta-analysis Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis (BMC infectious diseases, 2021) Meta-analysis Network meta-analysis of post-exposure prophylaxis randomized clinical trials (HIV medicine, 2021) Systematic review Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV: A Systematic Review (Clinical pharmacokinetics, 2023) Systematic review Therapeutic Drug Monitoring of HIV Antiretroviral Drugs in Pregnancy: A Narrative Review (Therapeutic drug monitoring, 2020) Systematic review Meta-analysis and systematic review of the efficacy and resistance for human immunodeficiency virus type 1 integrase strand transfer inhibitors (International journal of antimicrobial agents, 2019) Clinical trial publication Immediate and delayed switches to tenofovir DF-containing, ainuovirine-based antiretroviral regimen: the SPRINT extensional study (BMC medicine, 2025) Clinical trial publication Pharmacokinetics, safety and efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in children with HIV aged from 2 years and weighing at least 14 kg (Journal of the International AIDS Society, 2025) Clinical trial publication Bictegravir/emtricitabine/tenofovir alafenamide in adults with HIV-1 and end-stage kidney disease on chronic haemodialysis (HIV medicine, 2025) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
EMTRICITABINE	Small molecule	Approved	Strong	100	8 trials 26 Cochrane 44 Meta-analysis 782 Trial pubs 628 RCT View evidence Registry trials NCT03502005 — Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1 (COMPLETED) PHASE4 NCT00978237 — Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients (COMPLETED) PHASE4 NCT05979311 — A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy (ACTIVE_NOT_RECRUITING) PHASE3 NCT01118871 — The First Failure Study (TERMINATED) PHASE4 NCT04898699 — IPrEP Men's Study: Expanding the Reach of Prevention for Men in Kisumu, Kenya (COMPLETED) EARLY_PHASE1 NCT03512964 — Rapid HIV Treatment Initiation, Access and Engagement in Care (COMPLETED) NA NCT00433992 — Metabolic Effects of Non-Thymidine Analogue Anti-HIV Medications (COMPLETED) NCT01533272 — Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1:FOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC (MARAVI-PEP) (COMPLETED) PHASE4 Published literature Cochrane review Efficacy and safety of doravirine/islatravir for HIV-1: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials (HIV research & clinical practice, 2026) Cochrane review Lenacapavir as pre-exposure prophylaxis for HIV prevention (The Cochrane database of systematic reviews, 2026) Cochrane review Rapid start with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as initial treatment in people with human immunodeficiency virus-1 (HIV-1): A systematic literature review of clinical and patient-reported outcomes (HIV medicine, 2025) Cochrane review Comparative safety of B/F/TAF versus other antiretroviral therapy regimens for treatment-naïve people with HIV-1: a systematic literature review and network meta-analysis (Journal of comparative effectiveness research, 2025) Cochrane review Comparison of treatment-emergent resistance-associated mutations and discontinuation due to adverse events among integrase strand transfer inhibitor-based single-tablet regimens and cabotegravir + rilpivirine for the treatment of virologically suppressed people with HIV: A systematic literature review and network meta-analysis (HIV medicine, 2025) Meta-analysis Comparative safety of B/F/TAF versus other antiretroviral therapy regimens for treatment-experienced people with HIV-1: a systematic literature review and network meta-analysis (Journal of comparative effectiveness research, 2026) Systematic review Oral pre-exposure prophylaxis initiation, continuation and adherence among pregnant and postpartum women receiving antenatal and postnatal care: a systematic review (Journal of the International AIDS Society, 2025) Clinical trial publication Cardiometabolic impact of dolutegravir as second-line therapy: secondary analysis of a randomized controlled trial (AIDS (London, England), 2026) Clinical trial publication Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial (The lancet. HIV, 2026) Clinical trial publication Evaluating B/F/TAF at the first HIV-specialist appointment in antiretroviral naive persons living with HIV: the bifast study (BMC infectious diseases, 2026) Clinical trial publication Safety, acceptability, and adherence to dapivirine vaginal ring and oral pre-exposure prophylaxis for HIV prevention in the second trimester of pregnancy: a multicountry, open-label, phase 3b randomised trial (The lancet. HIV, 2026) Clinical trial publication Short-cycle three-day-per-week efavirenz/emtricitabine/tenofovir disoproxil fumarate therapy: a seven-year extension study (The Journal of antimicrobial chemotherapy, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
ENFUVIRTIDE	Biologic	Approved	Strong	100	8 trials 2 Meta-analysis 105 Trial pubs 64 RCT View evidence Registry trials NCT00051831 — Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults (COMPLETED) NA NCT00488059 — A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients (TERMINATED) PHASE4 NCT02302547 — Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (COMPLETED) PHASE3 NCT00925756 — CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery (COMPLETED) PHASE4 NCT00192660 — HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001) (COMPLETED) PHASE4 NCT02569502 — A Study of Enfuvirtide (Fuzeon) in Patients With Advanced Human Immunodeficiency Virus-1 (HIV-1) Infection (COMPLETED) PHASE4 NCT00326963 — BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. (COMPLETED) PHASE4 NCT00050856 — Fuzeon (Enfuvirtide) Early Access Program for Patients With HIV-1 Infection (COMPLETED) PHASE3 Published literature Meta-analysis Efficacy of new antiretroviral drugs in treatment-experienced HIV-infected patients: a systematic review and meta-analysis of recent randomized controlled trials (HIV medicine, 2012) Meta-analysis Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations (HIV clinical trials, 2006) Clinical trial publication Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study (The lancet. HIV, 2020) Clinical trial publication Metabolic, mitochondrial, renal and hepatic safety of enfuvirtide and raltegravir antiretroviral administration: Randomized crossover clinical trial in healthy volunteers (PloS one, 2019) Clinical trial publication Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial (AIDS research and therapy, 2016) Clinical trial publication Assessment of etravirine resistance in HIV-1-infected paediatric patients using population and deep sequencing: final results of the PIANO study (Antiviral therapy, 2016) Clinical trial publication Safety and Efficacy of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Adults Undergoing Autologous or Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies (Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016) Randomized controlled trial Pharmacokinetics of sifuvirtide in treatment-naive and treatment-experienced HIV-infected patients (Journal of pharmaceutical sciences, 2014) Randomized controlled trial Decreases in inflammatory and coagulation biomarkers levels in HIV-infected patients switching from enfuvirtide to raltegravir: ANRS 138 substudy (The Journal of infectious diseases, 2013) Randomized controlled trial Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo) (Antimicrobial agents and chemotherapy, 2013) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
ETRAVIRINE	Small molecule	Approved	Strong	100	8 trials 2 Cochrane 3 Meta-analysis 79 Trial pubs 38 RCT View evidence Registry trials NCT01118871 — The First Failure Study (TERMINATED) PHASE4 NCT02302547 — Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (COMPLETED) PHASE3 NCT00925756 — CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery (COMPLETED) PHASE4 NCT01422330 — A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients (COMPLETED) PHASE4 NCT01034917 — Switching From Protease Inhibitor (PI) to Etravirine in HIV-1 Infected Subjects With Viremia Suppression (COMPLETED) PHASE3 NCT00782301 — Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients (WITHDRAWN) PHASE4 NCT00531323 — TMC 125 Blood Levels Study (COMPLETED) PHASE1 NCT00903682 — A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients (COMPLETED) PHASE2 Published literature Cochrane review Second- and Third-line Antiretroviral Therapy for Children and Adolescents: A Scoping Review (The Pediatric infectious disease journal, 2017) Cochrane review Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults (Journal of infection and public health, 2015) Meta-analysis Interactions of Antiretroviral Drugs with Food, Beverages, Dietary Supplements, and Alcohol: A Systematic Review and Meta-analyses (AIDS and behavior, 2023) Meta-analysis Efficacy of new antiretroviral drugs in treatment-experienced HIV-infected patients: a systematic review and meta-analysis of recent randomized controlled trials (HIV medicine, 2012) Meta-analysis Modelling-based prediction of clinical benefits from etravirine in the TMC125-C223 trial (HIV clinical trials, 2007) Systematic review Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV: A Systematic Review (Clinical pharmacokinetics, 2023) Clinical trial publication Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087) (Clinical cancer research : an official journal of the American Association for Cancer Research, 2023) Clinical trial publication Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen (The Journal of antimicrobial chemotherapy, 2021) Clinical trial publication Characterization of viral rebounds on dual etravirine/raltegravir maintenance therapy (ANRS-163 ETRAL trial) (The Journal of antimicrobial chemotherapy, 2020) Clinical trial publication Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study (The lancet. HIV, 2019) Clinical trial publication Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL Study (Pharmacotherapy, 2019) Randomized controlled trial Efficacy and safety of lersivirine versus etravirine for the treatment of HIV-1 infection in patients with prior non-nucleoside reverse transcriptase inhibitor (NNRTI) use and evidence of NNRTI resistance: a randomized phase 2B trial (HIV clinical trials, 2014) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
FOSAMPRENAVIR CALCIUM	Small molecule	Approved	Strong	100	8 trials View evidence Registry trials NCT01054586 — Fosamprenavir in Pts With Hepatic Impairment (COMPLETED) NCT00089583 — 48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection (COMPLETED) PHASE2 NCT02302547 — Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (COMPLETED) PHASE3 NCT00966329 — Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects (COMPLETED) PHASE4 NCT00148785 — A Pharmacokinetic (PK) Study of a Combination of Indinavir, Ritonavir, and Amprenavir (COMPLETED) PHASE4 NCT00242840 — Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir) (COMPLETED) PHASE3 NCT00122603 — Dual Boosted Protease Inhibitor Regimens Without Any Additional Antiretroviral Therapy in HIV-1 Infected Patients (ANRS127) (COMPLETED) PHASE2 NCT01054638 — HIV Treatment and CVD Events (COMPLETED) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
IBALIZUMAB	Biologic	Approved	Strong	100	8 trials 4 Trial pubs 3 RCT View evidence Registry trials NCT01292174 — Safety Study of Ibalizumab Subcutaneous Injection in Healthy Volunteers (COMPLETED) PHASE1 NCT00784147 — Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1 (COMPLETED) PHASE2 NCT02707861 — Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1 (COMPLETED) PHASE3 NCT05890963 — 10E8.4/iMab Bispecific Antibody and VRC07-523LS Monoclonal Antibody in HIV-infected Adults (ACTIVE_NOT_RECRUITING) PHASE1 NCT00089700 — TNX-355 With Optimized Background Therapy (OBT) in Treatment-Experienced Subjects With HIV-1 (UNKNOWN) PHASE2 NCT02475629 — Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV (COMPLETED) PHASE3 NCT02028819 — Compassionate Use of Ibalizumab for the Treatment of HIV Infection (NO_LONGER_AVAILABLE) NCT03913195 — Study of the Safety of Trogarzo™ Administered as an Undiluted "IV Push" or an Intramuscular Injection (COMPLETED) PHASE3 Published literature Systematic review Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV: A Systematic Review (Clinical pharmacokinetics, 2023) Systematic review Indirect Treatment Comparisons of Lenacapavir Plus Optimized Background Regimen Versus Other Treatments for Multidrug-Resistant Human Immunodeficiency Virus (Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2023) Systematic review Comparative Efficacy and Safety of Fostemsavir in Heavily Treatment-Experienced People With HIV-1 (Clinical therapeutics, 2022) Clinical trial publication Efficacy and Safety of 2 Fixed Doses of Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced HIV-Positive Individuals (Journal of acquired immune deficiency syndromes (1999), 2024) Clinical trial publication Efficacy, Pharmacokinetics, and Safety Over 48 Weeks With Ibalizumab-Based Therapy in Treatment-Experienced Adults Infected With HIV-1: A Phase 2a Study (Journal of acquired immune deficiency syndromes (1999), 2021) Clinical trial publication Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1 (The New England journal of medicine, 2018) Clinical trial publication Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults (Antimicrobial agents and chemotherapy, 2009) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
LAMIVUDINE	Small molecule	Approved	Strong	100	8 trials 30 Cochrane 49 Meta-analysis 1087 Trial pubs 750 RCT View evidence Registry trials NCT00000875 — Controlled Clinical Trial of Antiviral Cytotoxic T Lymphocyte (CTL) Infusion Following Combination Antiretroviral Drug Therapy for Asymptomatic HIV-1 Infection (TERMINATED) NA NCT01511237 — Perinatal Antiretroviral Intensification for PMTCT of HIV in Late Comers (COMPLETED) PHASE3 NCT00087945 — Blood Levels of Abacavir in HIV Infected Adolescents (COMPLETED) NA NCT03311945 — Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM (COMPLETED) PHASE3 NCT00978237 — Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients (COMPLETED) PHASE4 NCT05979311 — A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy (ACTIVE_NOT_RECRUITING) PHASE3 NCT00004998 — Safety and Effectiveness of a New Anti-HIV Drug (AG1549) in Combination With Other Anti-HIV Drugs in HIV-Infected Patients (SUSPENDED) PHASE2 NCT00000887 — A Study to Evaluate the Safety and Tolerance of Nelfinavir (NFV) Given With Zidovudine (ZDV) and Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants (COMPLETED) PHASE1 Published literature Cochrane review Virological outcomes of dolutegravir-based versus other antiretroviral regimens in people living with HIV: A systematic review and meta-analysis (BMC infectious diseases, 2026) Cochrane review Comparison of treatment-emergent resistance-associated mutations and discontinuation due to adverse events among integrase strand transfer inhibitor-based single-tablet regimens and cabotegravir + rilpivirine for the treatment of virologically suppressed people with HIV: A systematic literature review and network meta-analysis (HIV medicine, 2025) Cochrane review A Systematical Review on ART Use in HTLV Infection: Clinical, Virological, and Immunological Outcomes (Pathogens (Basel, Switzerland), 2024) Cochrane review Comparison of safety and effectiveness of antiretroviral therapy regimens among pregnant women living with HIV at preconception or during pregnancy: a systematic review and network meta-analysis of randomized trials (BMC infectious diseases, 2024) Cochrane review Antivirals for prevention of hepatitis B virus mother-to-child transmission in human immunodeficiency virus positive pregnant women co-infected with hepatitis B virus (The Cochrane database of systematic reviews, 2023) Meta-analysis Association of nucleoside reverse transcriptase inhibitors with adverse perinatal outcomes in pregnant women living with HIV: systematic review and meta-analysis (Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2025) Meta-analysis Risk of viral failure after simplification therapy without using integrase inhibitors compared with maintenance of triple antiretroviral therapy: A systematic review and meta-analysis (The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2024) Systematic review Dolutegravir + lamivudine effectiveness and tolerability in real-world cohorts with HIV-1 across Asia and South America: A systematic literature review (Medicine, 2025) Clinical trial publication Exposure-response modeling of QTc interval and creatine kinase-MB in healthy people and treatment-naïve adults living with HIV-1 treated with ainuovirine monotherapy or combined with lamivudine and tenofovir DF (European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2026) Clinical trial publication Efficacy and safety of short-cycle, dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a multicentre, open-label, randomised, parallel, two-arm, non-inferiority trial (The lancet. HIV, 2026) Clinical trial publication Comparative evaluation of human T lymphocytes in HIV patients treated with lamivudine + zidovudine combined with nevirapine versus efavirenz (Medicine, 2026) Clinical trial publication Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial (Nature communications, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
LOPINAVIR	Small molecule	Approved	Strong	100	8 trials 12 Cochrane 30 Meta-analysis 525 Trial pubs 342 RCT View evidence Registry trials NCT00978237 — Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients (COMPLETED) PHASE4 NCT01296152 — Pharmacokinetic Interactions Between DMPA and LPV/r Among HIV-Infected Women (COMPLETED) PHASE2 NCT05850728 — First in Human Study of TLC-ART 101 (ACTU 2001) (COMPLETED) PHASE1 NCT00585793 — Relationship Between HIV-1 Subtype and ARV Response (COMPLETED) NCT01533272 — Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1:FOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC (MARAVI-PEP) (COMPLETED) PHASE4 NCT02369965 — Test Albuvirtide in Experienced Patients (COMPLETED) PHASE3 NCT00099632 — Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During Pregnancy (COMPLETED) PHASE2 NCT00437476 — Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Antiretroviral (ARV) Naive Patients Starting Treatment With Anti-HCV Therapy (UNKNOWN) PHASE3 Published literature Cochrane review Effectiveness and safety of darunavir and lopinavir for treating children and adolescents living with HIV: a systematic review (BMC infectious diseases, 2026) Cochrane review Efficacy of artemisinin-based combination therapy (ACT) in people living with HIV (PLHIV) diagnosed with uncomplicated Plasmodium falciparum malaria in Africa: a WWARN systematic review (Malaria journal, 2025) Cochrane review Antivirals for prevention of hepatitis B virus mother-to-child transmission in human immunodeficiency virus positive pregnant women co-infected with hepatitis B virus (The Cochrane database of systematic reviews, 2023) Cochrane review Adverse perinatal outcomes associated with antiretroviral therapy regimens: systematic review and network meta-analysis (AIDS (London, England), 2020) Cochrane review Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysis (The lancet. HIV, 2017) Meta-analysis Adverse perinatal outcomes associated with different classes of antiretroviral drugs in pregnant women with HIV (AIDS (London, England), 2025) Meta-analysis Interactions of Antiretroviral Drugs with Food, Beverages, Dietary Supplements, and Alcohol: A Systematic Review and Meta-analyses (AIDS and behavior, 2023) Meta-analysis Atazanavir / ritonavir versus Lopinavir / ritonavir-based combined antiretroviral therapy (cART) for HIV-1 infection: a systematic review and meta-analysis (African health sciences, 2020) Meta-analysis Network meta-analysis of post-exposure prophylaxis randomized clinical trials (HIV medicine, 2021) Systematic review Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV, Part II: Drugs Licensed Before 2005 (Clinical pharmacokinetics, 2024) Clinical trial publication Weight gain, body composition, and metabolic parameters of dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: an ancillary analysis of the ODYSSEY trial (The Lancet. Child & adolescent health, 2026) Clinical trial publication Pharmacokinetics of Dexamethasone in Tuberculous Meningitis (Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
MARAVIROC	Small molecule	Approved	Strong	100	8 trials 5 Cochrane 11 Meta-analysis 124 Trial pubs 90 RCT View evidence Registry trials NCT00821535 — Investigation Of Safety And Pharmacokinetics Following A Single Oral Dose Of 300 Mg Maraviroc In Healthy Male Japanese Volunteers (COMPLETED) PHASE1 NCT01533272 — Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1:FOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC (MARAVI-PEP) (COMPLETED) PHASE4 NCT00665561 — Prospective Observational Epidemiologic Study of Maraviroc's Safety (COMPLETED) NCT03708861 — Pharmacokinetics of Maraviroc and Boosted Atazanavir Dual Regimen in Stable HIV-infected Patients (WITHDRAWN) PHASE3 NCT00992654 — A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India (NO_LONGER_AVAILABLE) NCT02961829 — Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure (COMPLETED) NA NCT02302547 — Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (COMPLETED) PHASE3 NCT01204905 — R5 Integrase Study in HIV-1 Naive Patients (COMPLETED) NA Published literature Cochrane review Effectiveness of interventions on cognitive decline risk for people living with HIV on antiretroviral therapy: a systematic review (The lancet. Healthy longevity, 2026) Cochrane review Risk of failure in dual therapy versus triple therapy in naïve HIV patients: a systematic review and meta-analysis (Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2021) Cochrane review Atrial fibrillation and human immunodeficiency virus type-1 infection: a systematic review. Implications for anticoagulant and antiarrhythmic therapy (British journal of clinical pharmacology, 2019) Cochrane review Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis (The lancet. HIV, 2016) Cochrane review Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (PloS one, 2015) Meta-analysis Risk of viral failure after simplification therapy without using integrase inhibitors compared with maintenance of triple antiretroviral therapy: A systematic review and meta-analysis (The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2024) Meta-analysis Network meta-analysis of post-exposure prophylaxis randomized clinical trials (HIV medicine, 2021) Meta-analysis HIV-1 subtype C predicted co-receptor tropism in Africa: an individual sequence level meta-analysis (AIDS research and therapy, 2020) Systematic review Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV: A Systematic Review (Clinical pharmacokinetics, 2023) Clinical trial publication Switching to Low Neurotoxic Antiretrovirals to Improve Neurocognition Among People Living With HIV-1-Associated Neurocognitive Disorder: The MARAND-X Randomized Clinical Trial (Journal of acquired immune deficiency syndromes (1999), 2024) Clinical trial publication Pharmacologic Drug Detection and Self-Reported Adherence in the HPTN069/ACTG5305 Phase II PrEP Trial (AIDS and behavior, 2024) Clinical trial publication MAVMET trial: maraviroc and/or metformin for metabolic dysfunction associated fatty liver disease in adults with suppressed HIV (AIDS (London, England), 2024) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
NEVIRAPINE	Small molecule	Approved	Strong	100	8 trials 29 Cochrane 50 Meta-analysis 604 Trial pubs 393 RCT View evidence Registry trials NCT01511237 — Perinatal Antiretroviral Intensification for PMTCT of HIV in Late Comers (COMPLETED) PHASE3 NCT00001135 — A Study of Nevirapine to Prevent HIV Transmission From Mothers to Their Infants (COMPLETED) PHASE3 NCT00703898 — Durability of Nevirapine-Based Antiretroviral Regimen (COMPLETED) PHASE4 NCT00986063 — Genotype Based Personalized Prescription of Nevirapine (COMPLETED) PHASE4 NCT00099632 — Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During Pregnancy (COMPLETED) PHASE2 NCT03088410 — Study of HIV-Infected and Uninfected Pregnant Woman/Child Dyads in Gaborone, Botswana (COMPLETED) PHASE4 NCT01728961 — Pharmacology of Antimalarial Therapy With or Without Antiretroviral Therapy (TERMINATED) PHASE4 NCT00427297 — Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya (TERMINATED) PHASE3 Published literature Cochrane review Insights from systematic reviews (2019-2024) and drug interaction database analysis in people with HIV and comorbidities (International journal of STD & AIDS, 2026) Cochrane review Efficacy of artemisinin-based combination therapy (ACT) in people living with HIV (PLHIV) diagnosed with uncomplicated Plasmodium falciparum malaria in Africa: a WWARN systematic review (Malaria journal, 2025) Cochrane review Associations between human leukocyte antigen polymorphisms and hypersensitivity to antiretroviral therapy in patients with human immunodeficiency virus: a meta-analysis (BMC infectious diseases, 2019) Cochrane review Comparative safety and effectiveness of perinatal antiretroviral therapies for HIV-infected women and their children: Systematic review and network meta-analysis including different study designs (PloS one, 2018) Cochrane review Optimal Antiretroviral Prophylaxis in Infants at High Risk of Acquiring HIV: A Systematic Review (The Pediatric infectious disease journal, 2018) Meta-analysis Burden of virologic failure, and its determinants among HIV positive children in East Africa: a systematic review and meta-analysis (African health sciences, 2024) Meta-analysis Epidemiology of Antiretroviral Therapy Related Adverse Drug Reactions and its Predictors Among Patients with Human Immunodeficiency Virus/AIDS in Ethiopia: A Systematic Review and Meta-analysis (Journal of the International Association of Providers of AIDS Care, 2025) Meta-analysis Magnitude and characteristics of unsuppressed HIV viral load in children and adolescents on antiretroviral therapy in sub-Saharan Africa: a systematic review and meta-analysis (The lancet. HIV, 2025) Meta-analysis Prevalence and predictors of virological failure among the people living with HIV on antiretroviral treatment in East Africa: evidence from a systematic review with meta-analysis and meta-regression of published studies from 2016 to 2023 (HIV research & clinical practice, 2025) Meta-analysis Risk of viral failure after simplification therapy without using integrase inhibitors compared with maintenance of triple antiretroviral therapy: A systematic review and meta-analysis (The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2024) Clinical trial publication Comparative evaluation of human T lymphocytes in HIV patients treated with lamivudine + zidovudine combined with nevirapine versus efavirenz (Medicine, 2026) Clinical trial publication Regional Variations of Rates and Determinants of Drug Resistance Mutations in People Failing First-line Therapy for HIV-1: A Substudy from the D2EFT Phase 3b/4 Clinical Trial (Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
NICOTINE	Small molecule	Approved	Strong	100	8 trials 1 Cochrane 2 Meta-analysis 47 Trial pubs 45 RCT View evidence Registry trials NCT05162911 — Implementing Tobacco Use Treatment in HIV Clinics Vietnam (COMPLETED) NA NCT03904186 — Effectiveness of an Integrated Treatment to Address Smoking Cessation and Anxiety/ Depression in People Living With HIV (COMPLETED) NA NCT06880705 — The Trans-Led Care Study (RECRUITING) NA NCT05852860 — A Patient-Oriented Research Mentoring Program in Tobacco Dependence and Implementation Science Research (ACTIVE_NOT_RECRUITING) NA NCT01393301 — Integrated Treatment for Smoking Cessation & Anxiety in People With HIV (COMPLETED) NA NCT03224741 — Behavioral Economics Field Experiment in HIV Testing (COMPLETED) NA NCT02781090 — RCT of an Internet Cessation Program Plus Online Social Network for HIV+ Smokers (COMPLETED) NA NCT05030766 — Testing Integrative Smoking Cessation for HIV Patients (COMPLETED) PHASE4 Published literature Cochrane review Interventions for tobacco use cessation in people living with HIV (The Cochrane database of systematic reviews, 2024) Meta-analysis Meta-Analysis on Nicotine's Modulation of HIV-Associated Dementia (Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2022) Clinical trial publication Clinical Pharmacists, Medications, and Contingency Management for Targeting Smoking in HIV Clinics: A Randomized Clinical Trial (JAMA network open, 2026) Clinical trial publication Effectiveness of behavioural tobacco cessation interventions with and without pharmacotherapy among people living with HIV in Viet Nam: a three-arm pragmatic randomised controlled trial (The Lancet. Global health, 2026) Clinical trial publication Assessing the impact of nicotinic partial agonists compared to NRT on opioid and cigarette use: A secondary analysis investigating treatment outcomes for co-occurring nicotine and opioid use (Journal of substance use and addiction treatment, 2026) Clinical trial publication Population reach, feasibility and acceptability of digital therapeutics for smoking cessation among people living with HIV: Results of the Quitting Matters pilot trial (Drug and alcohol dependence, 2026) Clinical trial publication Galantamine for 12 weeks does not improve neurocognition or immune activation in ART-suppressed people with HIV (AIDS (London, England), 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
RALTEGRAVIR POTASSIUM	Small molecule	Approved	Strong	100	8 trials View evidence Registry trials NCT03311945 — Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM (COMPLETED) PHASE3 NCT00672932 — Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 Patients (COMPLETED) NA NCT00488059 — A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients (TERMINATED) PHASE4 NCT00515827 — Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load (COMPLETED) PHASE2 NCT01854762 — Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV Infection (TERMINATED) PHASE2, PHASE3 NCT00772551 — Raltegravir and Ezetimibe PK Study (COMPLETED) PHASE1 NCT02708342 — Observational, Retrospective Analysis in HIV-1 Infected Patients. (ORASWIRAL) (COMPLETED) NCT00764946 — A Study of Raltegravir in a Diverse Cohort of HIV-Infected Patients (0518-055) (COMPLETED) PHASE3 CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
RIFABUTIN	Small molecule	Approved	Strong	100	8 trials 4 Cochrane 3 Meta-analysis 65 Trial pubs 45 RCT View evidence Registry trials NCT01894776 — A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of Maraviroc (COMPLETED) PHASE1 NCT00018083 — Intensive Pharmacokinetics of the Nelfinavir-Rifabutin Interaction in Patients With HIV-Related Tuberculosis Treated With a Rifabutin-Based Regimen (UNKNOWN) NA NCT00001047 — Study of Four Different Treatment Approaches for Patients Who Have Mycobacterium Avium Complex Disease (MAC) Plus AIDS (COMPLETED) PHASE3 NCT00001058 — A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients With AIDS (COMPLETED) PHASE2 NCT00646776 — Drug Interaction Study (COMPLETED) PHASE1 NCT00023400 — TBTC Study 23B:Intensive PK of the Nelfinavir Rifabutin Interaction in Patients With HIV-TB (COMPLETED) PHASE4 NCT00000877 — Study of How Indinavir (an Anti-HIV Drug) and Rifabutin (a Drug Used to Treat MAC, an HIV-Associated Disease) Interact in HIV-Positive and HIV-Negative Adults (COMPLETED) PHASE1 NCT00002267 — Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial (COMPLETED) NA Published literature Cochrane review Interventions for the prevention of mycobacterium avium complex in adults and children with HIV (The Cochrane database of systematic reviews, 2013) Cochrane review HIV: primary and secondary prophylaxis for opportunistic infections (BMJ clinical evidence, 2010) Cochrane review HIV: treating tuberculosis (BMJ clinical evidence, 2009) Cochrane review Tuberculosis in people with HIV (BMJ clinical evidence, 2007) Meta-analysis Comparing clinical outcomes of antibiotics for treating Mycobacterium avium complex infection in adults with HIV: a systematic review and network meta-analysis (AIDS (London, England), 2026) Meta-analysis Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis (Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010) Systematic review Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review (Clinical pharmacokinetics, 2021) Clinical trial publication Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus-Tuberculosis Coinfection (Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021) Clinical trial publication Effect of SLCO1B1 Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis (Antimicrobial agents and chemotherapy, 2016) Clinical trial publication Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy (BMC pharmacology & toxicology, 2014) Clinical trial publication Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir (The Journal of antimicrobial chemotherapy, 2015) Clinical trial publication Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam (PloS one, 2014) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
RITONAVIR	Small molecule	Approved	Strong	100	8 trials 21 Cochrane 54 Meta-analysis 1235 Trial pubs 744 RCT View evidence Registry trials NCT00476502 — Study of Genetic Polymorphisms in Thai HIV-1 Infected Patients on SQV/r (COMPLETED) NCT00978237 — Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients (COMPLETED) PHASE4 NCT02289495 — A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects (TERMINATED) PHASE1 NCT01296152 — Pharmacokinetic Interactions Between DMPA and LPV/r Among HIV-Infected Women (COMPLETED) PHASE2 NCT05850728 — First in Human Study of TLC-ART 101 (ACTU 2001) (COMPLETED) PHASE1 NCT00585793 — Relationship Between HIV-1 Subtype and ARV Response (COMPLETED) NCT01118871 — The First Failure Study (TERMINATED) PHASE4 NCT01533272 — Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1:FOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC (MARAVI-PEP) (COMPLETED) PHASE4 Published literature Cochrane review Effectiveness and safety of darunavir and lopinavir for treating children and adolescents living with HIV: a systematic review (BMC infectious diseases, 2026) Cochrane review Insights from systematic reviews (2019-2024) and drug interaction database analysis in people with HIV and comorbidities (International journal of STD & AIDS, 2026) Cochrane review Efficacy of artemisinin-based combination therapy (ACT) in people living with HIV (PLHIV) diagnosed with uncomplicated Plasmodium falciparum malaria in Africa: a WWARN systematic review (Malaria journal, 2025) Cochrane review Antivirals for prevention of hepatitis B virus mother-to-child transmission in human immunodeficiency virus positive pregnant women co-infected with hepatitis B virus (The Cochrane database of systematic reviews, 2023) Cochrane review The effect of protease inhibitors-based antiretroviral therapy on serum/plasma interleukin-6 levels among PLHIV: a systematic review and meta-analysis (Journal of medical virology, 2022) Meta-analysis Adverse perinatal outcomes associated with different classes of antiretroviral drugs in pregnant women with HIV (AIDS (London, England), 2025) Meta-analysis Interactions of Antiretroviral Drugs with Food, Beverages, Dietary Supplements, and Alcohol: A Systematic Review and Meta-analyses (AIDS and behavior, 2023) Meta-analysis Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis (BMC infectious diseases, 2021) Meta-analysis Atazanavir / ritonavir versus Lopinavir / ritonavir-based combined antiretroviral therapy (cART) for HIV-1 infection: a systematic review and meta-analysis (African health sciences, 2020) Systematic review Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV, Part II: Drugs Licensed Before 2005 (Clinical pharmacokinetics, 2024) Clinical trial publication The dolutegravir failure cohort: A multi-country longitudinal cohort with a randomised clinical trial of continued dolutegravir versus switch to darunavir in people with viraemia while on dolutegravir in Sub-Saharan Africa (The Ndovu Study) protocol (PloS one, 2026) Clinical trial publication Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial (Nature communications, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
SAQUINAVIR	Small molecule	Approved	Strong	100	8 trials 1 Cochrane 4 Meta-analysis 250 Trial pubs 123 RCT View evidence Registry trials NCT00476502 — Study of Genetic Polymorphisms in Thai HIV-1 Infected Patients on SQV/r (COMPLETED) NCT00002334 — A Study of Zidovudine (AZT) Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients With Little or No Previous Treatment (COMPLETED) PHASE3 NCT00002367 — A Study of Saquinavir Soft Gelatin Capsules Plus Zidovudine Plus Lamivudine in the Treatment of HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs (COMPLETED) PHASE3 NCT00051831 — Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults (COMPLETED) NA NCT02302547 — Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (COMPLETED) PHASE3 NCT02239835 — Tipranavir and Ritonavir vs. Saquinavir and Ritonavir Used With Two Nucleoside Reverse Transcriptase Inhibitors in Single Protease Inhibitor-experienced HIV-1 Patients (TERMINATED) PHASE2 NCT00000848 — The Anti-HIV Effects of Saquinavir Soft Gelatin Capsules Versus Indinavir in Patients Who Have Used Saquinavir Hard Gelatin Capsules for One Year (COMPLETED) PHASE2 NCT00192608 — A 48-Week, Randomised, Study to Describe the Pharmacokinetic Profile and Durability of Atazanavir-Saquinavir-Ritonavir Once Daily and Describe the Pharmacokinetic Profile of Saquinavir-Ritonavir Using Saquinavir 500mg Formulation: the ASK-500 Study (COMPLETED) NA Published literature Cochrane review Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV (The Cochrane database of systematic reviews, 2013) Meta-analysis Interactions of Antiretroviral Drugs with Food, Beverages, Dietary Supplements, and Alcohol: A Systematic Review and Meta-analyses (AIDS and behavior, 2023) Meta-analysis Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels (HIV clinical trials, 2009) Meta-analysis Fosamprenavir clinical study meta-analysis in ART-naïve subjects: rare occurrence of virologic failure and selection of protease-associated mutations (HIV clinical trials, 2006) Systematic review Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review (Clinical pharmacokinetics, 2021) Systematic review Protecting the fetus against HIV infection: a systematic review of placental transfer of antiretrovirals (Clinical pharmacokinetics, 2014) Systematic review HIV-1 protease inhibitors. A review for clinicians (JAMA, 1997) Clinical trial publication Improved adipose tissue function with initiation of protease inhibitor-only ART (The Journal of antimicrobial chemotherapy, 2016) Clinical trial publication Effect of a modified saquinavir/ritonavir dosing regimen with lower dose lead-in phase on QTc interval, pharmacokinetics, antiviral activity and safety in treatment-naïve HIV-1-infected patients (Drugs in R&D, 2015) Clinical trial publication Provirus activation plus CD59 blockage triggers antibody-dependent complement-mediated lysis of latently HIV-1-infected cells (Journal of immunology (Baltimore, Md. : 1950), 2014) Clinical trial publication Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146 (Therapeutic drug monitoring, 2013) Clinical trial publication Effectiveness and safety of saquinavir/ritonavir in HIV-infected pregnant women: INEMA cohort (Medecine et maladies infectieuses, 2012) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
SOMATROPIN	Biologic	Approved	Strong	100	8 trials View evidence Registry trials NCT02196831 — Tesamorelin Effects on Liver Fat and Histology in HIV (COMPLETED) NA NCT03826160 — Growth Hormone Dynamics and Cardiac Steatosis in HIV (COMPLETED) NCT00287677 — Induction and Expansion of T Cell Repertoire Using Growth Hormone and Vaccination in HIV-1 Infected Patients (COMPLETED) PHASE4 NCT00608023 — TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy (COMPLETED) PHASE3 NCT00119769 — The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients (COMPLETED) PHASE4 NCT00286689 — Effects of Growth Hormone in Chronically Ill Children (WITHDRAWN) NA NCT02012556 — Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients (COMPLETED) PHASE1 NCT00489528 — Growth Hormone in the Treatment of HIV-Associated Wasting (COMPLETED) PHASE3 CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
TENOFOVIR ALAFENAMIDE FUMARATE	Small molecule	Approved	Strong	100	—	Open Targets, ChEMBL	ChEMBL Open Targets
TENOFOVIR DISOPROXIL FUMARATE	Small molecule	Approved	Strong	100	8 trials 22 Cochrane 37 Meta-analysis 520 Trial pubs 413 RCT View evidence Registry trials NCT01118871 — The First Failure Study (TERMINATED) PHASE4 NCT04898699 — IPrEP Men's Study: Expanding the Reach of Prevention for Men in Kisumu, Kenya (COMPLETED) EARLY_PHASE1 NCT05492565 — Seville Cohort of People at Substantial Risk for HIV Infection on Pre-exposure Prophylaxis (ENROLLING_BY_INVITATION) NCT00051831 — Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults (COMPLETED) NA NCT06766331 — Integrated Care Versus Usual Care for Opioid Use Disorder and Infectious Diseases in Veterans (NOT_YET_RECRUITING) NA NCT00099632 — Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During Pregnancy (COMPLETED) PHASE2 NCT01778413 — Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine (COMPLETED) PHASE4 NCT03708861 — Pharmacokinetics of Maraviroc and Boosted Atazanavir Dual Regimen in Stable HIV-infected Patients (WITHDRAWN) PHASE3 Published literature Cochrane review Lenacapavir as pre-exposure prophylaxis for HIV prevention (The Cochrane database of systematic reviews, 2026) Cochrane review Population Pharmacokinetic Simulations for Dose Optimization of Tenofovir Disoproxil Fumarate in HIV-Infected Patients with Moderate-to-Severe Renal Impairment (Journal of clinical pharmacology, 2025) Cochrane review Risk of dyslipidaemia in people living with HIV who are taking tenofovir alafenamide: a systematic review and meta-analysis (Journal of the International AIDS Society, 2024) Cochrane review Adherence and HIV Protection Thresholds for Emtricitabine and Tenofovir Disoproxil Fumarate Preexposure Prophylaxis among Cisgender Women: A Systematic Review (Current HIV/AIDS reports, 2024) Cochrane review Low clinical impact of HIV drug resistance mutations in oral pre-exposure prophylaxis: a systematic review and meta-analysis (AIDS research and therapy, 2024) Meta-analysis Chronic kidney disease among people living with HIV on TDF based regimen: A systematic review and meta-analysis (PloS one, 2025) Meta-analysis Association of nucleoside reverse transcriptase inhibitors with adverse perinatal outcomes in pregnant women living with HIV: systematic review and meta-analysis (Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2025) Meta-analysis Neuropsychiatric adverse events in tenofovir disoproxil fumarate- and tenofovir alafenamide-based HIV therapy and prophylaxis: a systematic review and meta‑analysis (Polish archives of internal medicine, 2024) Systematic review Performance of Adherence Measures for Oral, Tenofovir-Based HIV Pre-Exposure Prophylaxis: A Systematic Review (AIDS and behavior, 2025) Systematic review Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV, Part II: Drugs Licensed Before 2005 (Clinical pharmacokinetics, 2024) Clinical trial publication Exposure-response modeling of QTc interval and creatine kinase-MB in healthy people and treatment-naïve adults living with HIV-1 treated with ainuovirine monotherapy or combined with lamivudine and tenofovir DF (European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2026) Clinical trial publication Efficacy and safety of short-cycle, dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a multicentre, open-label, randomised, parallel, two-arm, non-inferiority trial (The lancet. HIV, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
TIPRANAVIR	Small molecule	Approved	Strong	100	8 trials 1 Cochrane 3 Meta-analysis 30 Trial pubs 25 RCT View evidence Registry trials NCT02302547 — Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (COMPLETED) PHASE3 NCT02239835 — Tipranavir and Ritonavir vs. Saquinavir and Ritonavir Used With Two Nucleoside Reverse Transcriptase Inhibitors in Single Protease Inhibitor-experienced HIV-1 Patients (TERMINATED) PHASE2 NCT00966329 — Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects (COMPLETED) PHASE4 NCT00925756 — CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery (COMPLETED) PHASE4 NCT00192660 — HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001) (COMPLETED) PHASE4 NCT02249130 — Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir (COMPLETED) PHASE2 NCT00056641 — Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients (COMPLETED) PHASE2 NCT02229760 — Effect of Steady State TPV/r on Intracellular Concentrations of Zidovudine and Carbovir for Patients With HIV (TERMINATED) PHASE1, PHASE2 Published literature Cochrane review Virologic response to tipranavir-ritonavir or darunavir-ritonavir based regimens in antiretroviral therapy experienced HIV-1 patients: a meta-analysis and meta-regression of randomized controlled clinical trials (PloS one, 2013) Meta-analysis Efficacy of new antiretroviral drugs in treatment-experienced HIV-infected patients: a systematic review and meta-analysis of recent randomized controlled trials (HIV medicine, 2012) Meta-analysis Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations (HIV clinical trials, 2006) Systematic review Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV, Part II: Drugs Licensed Before 2005 (Clinical pharmacokinetics, 2024) Systematic review Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV: A Systematic Review (Clinical pharmacokinetics, 2023) Clinical trial publication Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial (AIDS research and therapy, 2016) Clinical trial publication Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial (PloS one, 2016) Clinical trial publication Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race-ethnicity determine the degree of regimen complexity (HIV clinical trials, 2015) Clinical trial publication Efficacy and safety of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents: 5 years of experience (The Pediatric infectious disease journal, 2014) Clinical trial publication Boosted tipranavir versus darunavir in treatment-experienced patients: observational data from the randomized POTENT trial (Drugs in R&D, 2011) Randomized controlled trial Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial (The Journal of antimicrobial chemotherapy, 2011) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
ZIDOVUDINE	Small molecule	Approved	Strong	100	8 trials 37 Cochrane 48 Meta-analysis 1365 Trial pubs 880 RCT View evidence Registry trials NCT00000875 — Controlled Clinical Trial of Antiviral Cytotoxic T Lymphocyte (CTL) Infusion Following Combination Antiretroviral Drug Therapy for Asymptomatic HIV-1 Infection (TERMINATED) NA NCT01511237 — Perinatal Antiretroviral Intensification for PMTCT of HIV in Late Comers (COMPLETED) PHASE3 NCT00087945 — Blood Levels of Abacavir in HIV Infected Adolescents (COMPLETED) NA NCT00002334 — A Study of Zidovudine (AZT) Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients With Little or No Previous Treatment (COMPLETED) PHASE3 NCT00000734 — Evaluation of the Interaction Between High Dose Sulfamethoxazole/Trimethoprim and Zidovudine (COMPLETED) NA NCT00004998 — Safety and Effectiveness of a New Anti-HIV Drug (AG1549) in Combination With Other Anti-HIV Drugs in HIV-Infected Patients (SUSPENDED) PHASE2 NCT00000887 — A Study to Evaluate the Safety and Tolerance of Nelfinavir (NFV) Given With Zidovudine (ZDV) and Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants (COMPLETED) PHASE1 NCT01075152 — Cryptococcal Optimal ART Timing Trial (COMPLETED) PHASE4 Published literature Cochrane review Predictors of anemia among HIV-infected children in Ethiopia: systematic review and meta-analysis (Scientific reports, 2025) Cochrane review A Systematical Review on ART Use in HTLV Infection: Clinical, Virological, and Immunological Outcomes (Pathogens (Basel, Switzerland), 2024) Cochrane review Comparison of safety and effectiveness of antiretroviral therapy regimens among pregnant women living with HIV at preconception or during pregnancy: a systematic review and network meta-analysis of randomized trials (BMC infectious diseases, 2024) Cochrane review Antivirals for prevention of hepatitis B virus mother-to-child transmission in human immunodeficiency virus positive pregnant women co-infected with hepatitis B virus (The Cochrane database of systematic reviews, 2023) Cochrane review Does antiretroviral therapy cause congenital malformations? A systematic review and meta-analysis (Epidemiology and health, 2021) Meta-analysis Epidemiology of Antiretroviral Therapy Related Adverse Drug Reactions and its Predictors Among Patients with Human Immunodeficiency Virus/AIDS in Ethiopia: A Systematic Review and Meta-analysis (Journal of the International Association of Providers of AIDS Care, 2025) Meta-analysis Prevalence and risk factors of anemia among people living with HIV/AIDS in Southeast Asia: a systematic review and meta-analysis (BMC infectious diseases, 2025) Meta-analysis Association of nucleoside reverse transcriptase inhibitors with adverse perinatal outcomes in pregnant women living with HIV: systematic review and meta-analysis (Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2025) Systematic review Clinical Presentation, Etiology, and Outcomes of HIV-Associated Cardiomyopathy: A Systematic Review of Published Case Reports (Viruses, 2026) Clinical trial publication Acceptability of a Dolutegravir Oral Dispersible Film in Term Neonates Born to Mothers Living With HIV (Journal of the International AIDS Society, 2026) Clinical trial publication Comparative evaluation of human T lymphocytes in HIV patients treated with lamivudine + zidovudine combined with nevirapine versus efavirenz (Medicine, 2026) Clinical trial publication Regional Variations of Rates and Determinants of Drug Resistance Mutations in People Failing First-line Therapy for HIV-1: A Substudy from the D2EFT Phase 3b/4 Clinical Trial (Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
ACETAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
AMPHETAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
APOMORPHINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BICALUTAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CARBACHOL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CEFOTETAN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CHEMBL413	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CIPROFLOXACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CLOMIPRAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CYCLOPHOSPHAMIDE ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DIAZEPAM Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIETHYLSTILBESTROL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
EPIRUBICIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
EPIRUBICIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ETHOXZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
FLUMAZENIL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
FLUOROURACIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
IMIPRAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDAPAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDOMETHACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ISOSORBIDE DINITRATE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MAFENIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MECAMYLAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHOXSALEN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METOPROLOL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MIANSERIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NALIDIXIC ACID Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NORFLOXACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
OFLOXACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
PHENYTOIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
PRAZOSIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
SULBACTAM Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TACROLIMUS ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TAZOBACTAM Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TROGLITAZONE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ALDESLEUKIN	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
NALTREXONE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
PEGINTERFERON ALFA-2A	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
RIBAVIRIN	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
BUPRENORPHINE	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
CHEMBL104	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201561	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL1410	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL70663	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL91	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHOLECALCIFEROL	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
ETHAMBUTOL HYDROCHLORIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
HEPATITIS B VIRUS HBSAG SURFACE PROTEIN ANTIGEN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INDINAVIR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LEVOFLOXACIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
NELFINAVIR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PYRAZINAMIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PYRIDOXINE HYDROCHLORIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
RIFAMPIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DARAPLADIB Repurposing	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
FENRETINIDE Repurposing	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
FOLIC ACID	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
LEVONORGESTREL	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
MINOCYCLINE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
PRAVASTATIN SODIUM	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ACYCLOVIR SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALENDRONIC ACID	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ATORVASTATIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BLEOMYCIN SULFATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CHEMBL1017	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL105318	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL109	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL109831	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201134	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201821	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1276308	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL131	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL135	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1617	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL2107384	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL2109042	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL2109047	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL2110727	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL2218911	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL25	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL38700	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL468	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL503	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL5314347	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL547	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL571987	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL573	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL672	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL692	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL717	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL76	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL848	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL98	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CYANOCOBALAMIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DOXORUBICIN HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EPIRUBICIN HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ERGOCALCIFEROL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ETONOGESTREL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ETOPOSIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FILGRASTIM	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GABAPENTIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GALANTAMINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GINSENG, AMERICAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INTERFERON	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INTERFERON ALFA	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INTERFERON ALFA-2B	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MECHLORETHAMINE HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MEGESTROL ACETATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OBEFAZIMOD	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PENTOXIFYLLINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PREDNISONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PYRIDOXINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SORIVUDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TESTOSTERONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TESTOSTERONE ENANTHATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VINBLASTINE SULFATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VINCRISTINE SULFATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ZALCITABINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALPRENOLOL Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
AMIFLOXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
BROLAMFETAMINE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
CARZENIDE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIFLOXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIMECAMINE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ELLAGIC ACID Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ENISOPROST Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FENCAMFAMIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FLEROXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
IDOXIFENE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
LYSERGIDE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
MERAFLOXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
TENAMFETAMINE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ZIDAPAMIDE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
CYCLOPHOSPHAMIDE	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
CHEMBL1064	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL1237022	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL1237026	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL1471	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL1751	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL2109446	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL3545347	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL393220	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL504	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL638	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL70927	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL843	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL932	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL964	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CP1-1189	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
EFINEPTAKIN ALFA	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
INTERLEUKIN-7	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
METHADONE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PEPTIDE T	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PRETOMANID	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RIFAPENTINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SILYBIN A	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE CRM197	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TIFUVIRTIDE	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TUCIDINOSTAT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ZINC ACETATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ZINC SULFATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
(+/-)NICOTINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ABACAVIR	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ATAZANAVIR	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ATEZOLIZUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
AZITHROMYCIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BICTEGRAVIR	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BOCEPREVIR	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CEFTRIAXONE SODIUM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DACLATASVIR	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DARUNAVIR	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DARUNAVIR ETHANOLATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DIDANOSINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DOLUTEGRAVIR	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DOLUTEGRAVIR SODIUM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ELASOMERAN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
EMTRICITABINE, (+/-)-	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
EPOETIN ALFA	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ETHAMBUTOL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ETHINYL ESTRADIOL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FALDAPREVIR	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FIPRAVIRIMAT	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FIPRAVIRIMAT MESYLATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FOMIVIRSEN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FOSTEMSAVIR TROMETHAMINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GANCICLOVIR	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GLECAPREVIR	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
INDINAVIR SULFATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ISONIAZID	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LENACAPAVIR	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LENACAPAVIR SODIUM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LERONLIMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MOXIFLOXACIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
NALOXONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
NELFINAVIR MESYLATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ONDANSETRON	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PEMBROLIZUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PENICILLIN G POTASSIUM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PIBRENTASVIR	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
RALTEGRAVIR	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
RIFAMYCIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
RILPIVIRINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
RILPIVIRINE HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ROVAFOVIR ETALAFENAMIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ROVAFOVIR ETALAFENAMIDE CITRATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SAQUINAVIR MESYLATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SIMEPREVIR	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SOFOSBUVIR	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
STAVUDINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TELAPREVIR	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TENOFOVIR	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TENOFOVIR ALAFENAMIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TENOFOVIR DISOPROXIL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TENOFOVIR DISOPROXIL MALEATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TEROPAVIMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TOZINAMERAN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ZEGRUVIRIMAT	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ZEGRUVIRIMAT TOSYLATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ZINLIRVIMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
ABACAVIR SULFATE	Small molecule	Approved	Strong	100	8 trials 2 Trial pubs 2 RCT View evidence Registry trials NCT00087945 — Blood Levels of Abacavir in HIV Infected Adolescents (COMPLETED) NA NCT00978237 — Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients (COMPLETED) PHASE4 NCT00433992 — Metabolic Effects of Non-Thymidine Analogue Anti-HIV Medications (COMPLETED) NCT00001086 — A Study of Abacavir Plus Indinavir Sulfate Plus Efavirenz in HIV-Infected Patients (COMPLETED) PHASE2 NCT03760458 — The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age (COMPLETED) PHASE1, PHASE2 NCT00427297 — Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya (TERMINATED) PHASE3 NCT04155554 — Neurological Monitoring in Patients Switching From Dolutegravir Based Regimen to Bictegravir Based Regimen (UNKNOWN) PHASE3 NCT02708342 — Observational, Retrospective Analysis in HIV-1 Infected Patients. (ORASWIRAL) (COMPLETED) Published literature Clinical trial publication Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials (The lancet. HIV, 2024) Clinical trial publication Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment (AIDS (London, England), 2009) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
AMPRENAVIR	Small molecule	Approved	Strong	100	8 trials 1 Meta-analysis 77 Trial pubs 39 RCT View evidence Registry trials NCT00089583 — 48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection (COMPLETED) PHASE2 NCT00006591 — Ritonavir and Agenerase Treatment for Patients Who Have Failed Previous Anti-HIV Treatment (UNKNOWN) NA NCT00148785 — A Pharmacokinetic (PK) Study of a Combination of Indinavir, Ritonavir, and Amprenavir (COMPLETED) PHASE4 NCT00192660 — HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001) (COMPLETED) PHASE4 NCT00056641 — Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients (COMPLETED) PHASE2 NCT01054638 — HIV Treatment and CVD Events (COMPLETED) NCT00071760 — Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects (COMPLETED) PHASE2 NCT00001766 — Drug Interactions Among Anti-HIV Agents (COMPLETED) PHASE1 Published literature Meta-analysis Interactions of Antiretroviral Drugs with Food, Beverages, Dietary Supplements, and Alcohol: A Systematic Review and Meta-analyses (AIDS and behavior, 2023) Clinical trial publication Fosamprenavir with Ritonavir Pharmacokinetics during Pregnancy (Antimicrobial agents and chemotherapy, 2020) Clinical trial publication Population pharmacokinetic modeling and simulation of amprenavir following fosamprenavir/ritonavir administration for dose optimization in HIV infected pediatric patients (Journal of clinical pharmacology, 2014) Clinical trial publication Long-term safety study of fosamprenavir-containing regimens in HIV-1-infected patients (HIV clinical trials, 2013) Clinical trial publication Pharmacokinetics and 48-week safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2- to 18-year-old children (The Pediatric infectious disease journal, 2014) Clinical trial publication Pharmacokinetics, safety and antiviral activity of fosamprenavir/ritonavir-containing regimens in HIV-infected children aged 4 weeks to 2 years-48-week study data (The Pediatric infectious disease journal, 2014) Randomized controlled trial Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146 (Therapeutic drug monitoring, 2013) Randomized controlled trial Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers (HIV medicine, 2010) Randomized controlled trial Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance (The Journal of antimicrobial chemotherapy, 2009) Randomized controlled trial Effect of baseline viral susceptibility on response to darunavir/ritonavir versus control protease inhibitors in treatment-experienced HIV type 1-infected patients: POWER 1 and 2 (AIDS research and human retroviruses, 2008) Randomized controlled trial Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen (Antimicrobial agents and chemotherapy, 2008) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
ATAZANAVIR SULFATE	Small molecule	Approved	Strong	100	8 trials View evidence Registry trials NCT00357721 — Atazanavir Twice Daily (COMPLETED) PHASE1 NCT01232127 — Effects of Famotidine on the Pharmacokinetics of Atazanavir When Coadministered to Participants With HIV Infection (COMPLETED) PHASE4 NCT03708861 — Pharmacokinetics of Maraviroc and Boosted Atazanavir Dual Regimen in Stable HIV-infected Patients (WITHDRAWN) PHASE3 NCT01805427 — Antiretroviral Therapy and Extreme Weight (COMPLETED) NCT01691794 — Safety Sudy of Atazanavir Boosted With Ritonavir in the Treatment of HIV Infection in Pediatric Patients (COMPLETED) PHASE4 NCT00135356 — Study of Reyataz in HIV-infected Patients With Lipodystrophy Syndrome (COMPLETED) PHASE4 NCT02302547 — Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (COMPLETED) PHASE3 NCT00192608 — A 48-Week, Randomised, Study to Describe the Pharmacokinetic Profile and Durability of Atazanavir-Saquinavir-Ritonavir Once Daily and Describe the Pharmacokinetic Profile of Saquinavir-Ritonavir Using Saquinavir 500mg Formulation: the ASK-500 Study (COMPLETED) NA CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
CABOTEGRAVIR	Small molecule	Approved	Strong	100	8 trials 10 Cochrane 11 Meta-analysis 75 Trial pubs 47 RCT View evidence Registry trials NCT05152953 — Preparing for Pharmacy-based Delivery of Long-acting Injectable Antiretroviral Therapy (LAI-ART) (COMPLETED) NCT06565013 — Chemsex Health Evaluation With Extended Release System for HIV Treatment (NOT_YET_RECRUITING) NCT06145854 — Cisgender Female Patients Who Start on Long Acting Cabotegravir for PrEP (ACTIVE_NOT_RECRUITING) NCT04542070 — A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed (COMPLETED) PHASE3 NCT05949203 — Oregon PrEP at Home Study (UNKNOWN) NCT05986084 — Tshireletso: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Population in Botswana (ACTIVE_NOT_RECRUITING) PHASE4 NCT03635788 — The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE (ACTIVE_NOT_RECRUITING) PHASE3 NCT04484337 — Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants (COMPLETED) PHASE1 Published literature Cochrane review Lenacapavir as pre-exposure prophylaxis for HIV prevention (The Cochrane database of systematic reviews, 2026) Cochrane review The safety of cabotegravir in pregnancy: a systematic review and meta-analysis (BMC infectious diseases, 2025) Cochrane review Outcomes of real-world initiation of long-acting injectable cabotegravir and rilpivirine (LA-I CAB + RPV) in individuals with viraemia: A systematic review of baseline characteristics, virological failure outcomes and discontinuations (HIV medicine, 2026) Cochrane review Long-acting injectable cabotegravir and rilpivirine in observational cohort studies: A systematic review on virological failure, resistance and re-suppression outcomes in virally suppressed individuals living with HIV (HIV medicine, 2025) Cochrane review Comparison of treatment-emergent resistance-associated mutations and discontinuation due to adverse events among integrase strand transfer inhibitor-based single-tablet regimens and cabotegravir + rilpivirine for the treatment of virologically suppressed people with HIV: A systematic literature review and network meta-analysis (HIV medicine, 2025) Meta-analysis Rapid diagnostic tests, laboratory-based immunoassay and nucleic acid testing strategies for long-acting injectable pre-exposure prophylaxis: A systematic review and meta-analysis (PLoS medicine, 2026) Meta-analysis Cabotegravir Plus Rilpivirine Injection for Virally Suppressed Persons with HIV-1 infection: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (Clinical therapeutics, 2025) Systematic review High Virologic Suppression and Favorable Profiles of Two-Drug Antiretroviral Regimens in Africa: A Systematic Review of Current Evidence (Clinical pharmacology and therapeutics, 2025) Clinical trial publication Feasibility, Fidelity, and Effectiveness of Administering Long-Acting Cabotegravir + Rilpivirine in Infusion Centers in the United States: Findings From the Phase 4 GLACIER Implementation Study (Journal of the International Association of Providers of AIDS Care, 2026) Clinical trial publication Advancing youth HIV prevention and care in Uganda: stakeholder-informed innovations through implementation science, protocol for a randomized controlled trial (BMC health services research, 2026) Clinical trial publication Long-acting HIV pre-exposure prophylaxis integrated with community-based sexual and reproductive health services in South Africa (LAPIS): study protocol for a hybrid (1a) cluster randomised controlled phase 3B trial of effectiveness and implementation (BMC public health, 2026) Clinical trial publication Safety, antiviral activity, and pharmacokinetics of long-acting injectable cabotegravir-rilpivirine in virologically suppressed adolescents living with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multinational, phase 1/2, single-arm study (The lancet. HIV, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
CHEMBL3301594	Small molecule	Approved	Strong	100	—	ChEMBL	ChEMBL Open Targets
COBICISTAT	Small molecule	Approved	Strong	100	—	Open Targets, ChEMBL	ChEMBL Open Targets
DORAVIRINE	Small molecule	Approved	Strong	100	8 trials 2 Cochrane 3 Meta-analysis 34 Trial pubs 25 RCT View evidence Registry trials NCT05766501 — A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054) (ACTIVE_NOT_RECRUITING) PHASE3 NCT04665375 — Can INSTI-associated Weight Gain be Halted or Reversed With a Switch to Doravirine/Lamivudine/Tenofovir DF? (TERMINATED) PHASE4 NCT05477407 — Adipose Tissue After Switch to Doravirine (COMPLETED) NA NCT04233372 — Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo®) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study (COMPLETED) PHASE4 NCT03894124 — Pharmacokinetics of Plasma Doravirine Once Daily Over 72 Hours Following Drug Intake Cessation in Healthy Volunteers (COMPLETED) PHASE1 NCT05648201 — Study on PhArmacokinetics of First liNe Antiretrovirals in Healthy Breastfeeding Volunteers (COMPLETED) PHASE4 NCT06034938 — DOR/TDF/3TC Switch With M184V/I in People With Controlled HIV (Drive Off-Road) (RECRUITING) PHASE2 NCT01632345 — A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007) (COMPLETED) PHASE2 Published literature Cochrane review Efficacy and safety of doravirine/islatravir for HIV-1: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials (HIV research & clinical practice, 2026) Cochrane review Efficacy and safety of doravirine/islatravir for the treatment of HIV-1: a systematic review and meta-analysis of randomized controlled trials with GRADE assessment (European journal of clinical pharmacology, 2026) Meta-analysis Efficacy and safety of doravirine in treatment-naive HIV-1-infected adults: a systematic review and meta-analysis (Environmental science and pollution research international, 2021) Systematic review Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV: A Systematic Review (Clinical pharmacokinetics, 2023) Systematic review Clinical Impact of Virological Failure and Resistance Analysis Definitions used in Pivotal Clinical Trials of Initial Antiretroviral Treatment: A Systematic Review (AIDS reviews, 2018) Clinical trial publication Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial (The lancet. HIV, 2026) Clinical trial publication Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial (Lancet (London, England), 2026) Clinical trial publication Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial (Lancet (London, England), 2026) Clinical trial publication Doravirine Resistance Patterns Identified Through Week 192 in the DRIVE-FORWARD and DRIVE-AHEAD Phase 3 Clinical Trials (Journal of acquired immune deficiency syndromes (1999), 2026) Clinical trial publication Cardiovascular Risk Assessment Using the Atherosclerotic Cardiovascular Disease Risk Score Model after Continuing or Switching to a Doravirine-Based HIV Treatment Regimen (Journal of acquired immune deficiency syndromes (1999), 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
EFAVIRENZ	Small molecule	Approved	Strong	100	8 trials 26 Cochrane 61 Meta-analysis 819 Trial pubs 559 RCT View evidence Registry trials NCT03158857 — Hepatitis C Treatment Study in Myanmar (WITHDRAWN) NCT03502005 — Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1 (COMPLETED) PHASE4 NCT00978237 — Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients (COMPLETED) PHASE4 NCT01065792 — Stocrin Re-examination Study (0831-028) (COMPLETED) NCT01075152 — Cryptococcal Optimal ART Timing Trial (COMPLETED) PHASE4 NCT00001086 — A Study of Abacavir Plus Indinavir Sulfate Plus Efavirenz in HIV-Infected Patients (COMPLETED) PHASE2 NCT00427297 — Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya (TERMINATED) PHASE3 NCT01778413 — Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine (COMPLETED) PHASE4 Published literature Cochrane review Effectiveness of interventions on cognitive decline risk for people living with HIV on antiretroviral therapy: a systematic review (The lancet. Healthy longevity, 2026) Cochrane review Virological outcomes of dolutegravir-based versus other antiretroviral regimens in people living with HIV: A systematic review and meta-analysis (BMC infectious diseases, 2026) Cochrane review Insights from systematic reviews (2019-2024) and drug interaction database analysis in people with HIV and comorbidities (International journal of STD & AIDS, 2026) Cochrane review Efficacy of artemisinin-based combination therapy (ACT) in people living with HIV (PLHIV) diagnosed with uncomplicated Plasmodium falciparum malaria in Africa: a WWARN systematic review (Malaria journal, 2025) Cochrane review Cardiovascular disease and its risk factors among people living with HIV: A systematic review and meta-analysis (Journal of infection and public health, 2025) Meta-analysis Self-reported sleep disturbances among people living with HIV in China: A Systematic Review and Meta-Analysis (Behavioral sleep medicine, 2025) Meta-analysis Risk of viral failure after simplification therapy without using integrase inhibitors compared with maintenance of triple antiretroviral therapy: A systematic review and meta-analysis (The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2024) Meta-analysis Adverse perinatal outcomes associated with different classes of antiretroviral drugs in pregnant women with HIV (AIDS (London, England), 2025) Clinical trial publication Comparative evaluation of human T lymphocytes in HIV patients treated with lamivudine + zidovudine combined with nevirapine versus efavirenz (Medicine, 2026) Clinical trial publication Brain Structure of South African Children Born to Mothers on Dolutegravir Versus Efavirenz-Based Antiretroviral Therapy (Journal of the Pediatric Infectious Diseases Society, 2026) Clinical trial publication Initiation of dolutegravir vs efavirenz on 12- and 24-month weight, body mass index, blood pressure, and incident hypertension: A target trial emulation (Annals of epidemiology, 2026) Clinical trial publication HIV drug resistance amongst children and adolescents with viraemia in Lesotho and Tanzania: a nested analysis in the GIVE MOVE trial (The Journal of antimicrobial chemotherapy, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
ELVITEGRAVIR	Small molecule	Approved	Strong	100	8 trials 3 Cochrane 11 Meta-analysis 71 Trial pubs 50 RCT View evidence Registry trials NCT02302547 — Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (COMPLETED) PHASE3 NCT01694420 — Treatment of Acute HIV Infection With Quad Fixed-dose Combination (FDC) Tablet (COMPLETED) PHASE3 NCT00298350 — Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART. (COMPLETED) PHASE2 NCT00869557 — Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults (COMPLETED) PHASE2 NCT02306577 — STRIBILD in Non-Nucleoside Resistant Patients (SINNR STUDY) (UNKNOWN) NCT02351908 — Renal Integrase Study (COMPLETED) PHASE4 NCT02198443 — Comparison of Two Combinations in Antiretroviral Post-Exposure Prophylaxis for HIV-1: Tenofovir/Emtricitabine (Truvada ®) + Lopinavir/Ritonavir (Kaletra ®) vs Tenofovir/Emtricitabine/Cobicistat/Elvitegravir (Stribild ®). Prospective, Randomized, Open. (COMPLETED) PHASE4 NCT03205696 — Prevention and Treatment Continuum for Youth at HIV Risk, Acutely Infected and With Established HIV Infection (COMPLETED) Published literature Cochrane review Deep sequencing reveals underestimated burden of integrase inhibitor resistance mutations in people living with HIV: a global individual patient data meta-analysis (Emerging microbes & infections, 2025) Cochrane review Effects of different integrase strand transfer inhibitors on body weight in patients with HIV/AIDS: a network meta-analysis (BMC infectious diseases, 2022) Cochrane review Therapy-Emergent Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Patients: A Subgroup Meta-Analysis of Clinical Trials (PloS one, 2016) Meta-analysis Interactions of Antiretroviral Drugs with Food, Beverages, Dietary Supplements, and Alcohol: A Systematic Review and Meta-analyses (AIDS and behavior, 2023) Meta-analysis Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis (BMC infectious diseases, 2021) Meta-analysis Network meta-analysis of post-exposure prophylaxis randomized clinical trials (HIV medicine, 2021) Systematic review Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV: A Systematic Review (Clinical pharmacokinetics, 2023) Systematic review Therapeutic Drug Monitoring of HIV Antiretroviral Drugs in Pregnancy: A Narrative Review (Therapeutic drug monitoring, 2020) Systematic review Meta-analysis and systematic review of the efficacy and resistance for human immunodeficiency virus type 1 integrase strand transfer inhibitors (International journal of antimicrobial agents, 2019) Clinical trial publication Immediate and delayed switches to tenofovir DF-containing, ainuovirine-based antiretroviral regimen: the SPRINT extensional study (BMC medicine, 2025) Clinical trial publication Pharmacokinetics, safety and efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in children with HIV aged from 2 years and weighing at least 14 kg (Journal of the International AIDS Society, 2025) Clinical trial publication Bictegravir/emtricitabine/tenofovir alafenamide in adults with HIV-1 and end-stage kidney disease on chronic haemodialysis (HIV medicine, 2025) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
EMTRICITABINE	Small molecule	Approved	Strong	100	8 trials 26 Cochrane 44 Meta-analysis 782 Trial pubs 628 RCT View evidence Registry trials NCT03502005 — Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1 (COMPLETED) PHASE4 NCT00978237 — Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients (COMPLETED) PHASE4 NCT05979311 — A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy (ACTIVE_NOT_RECRUITING) PHASE3 NCT01118871 — The First Failure Study (TERMINATED) PHASE4 NCT04898699 — IPrEP Men's Study: Expanding the Reach of Prevention for Men in Kisumu, Kenya (COMPLETED) EARLY_PHASE1 NCT03512964 — Rapid HIV Treatment Initiation, Access and Engagement in Care (COMPLETED) NA NCT00433992 — Metabolic Effects of Non-Thymidine Analogue Anti-HIV Medications (COMPLETED) NCT01533272 — Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1:FOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC (MARAVI-PEP) (COMPLETED) PHASE4 Published literature Cochrane review Efficacy and safety of doravirine/islatravir for HIV-1: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials (HIV research & clinical practice, 2026) Cochrane review Lenacapavir as pre-exposure prophylaxis for HIV prevention (The Cochrane database of systematic reviews, 2026) Cochrane review Rapid start with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as initial treatment in people with human immunodeficiency virus-1 (HIV-1): A systematic literature review of clinical and patient-reported outcomes (HIV medicine, 2025) Cochrane review Comparative safety of B/F/TAF versus other antiretroviral therapy regimens for treatment-naïve people with HIV-1: a systematic literature review and network meta-analysis (Journal of comparative effectiveness research, 2025) Cochrane review Comparison of treatment-emergent resistance-associated mutations and discontinuation due to adverse events among integrase strand transfer inhibitor-based single-tablet regimens and cabotegravir + rilpivirine for the treatment of virologically suppressed people with HIV: A systematic literature review and network meta-analysis (HIV medicine, 2025) Meta-analysis Comparative safety of B/F/TAF versus other antiretroviral therapy regimens for treatment-experienced people with HIV-1: a systematic literature review and network meta-analysis (Journal of comparative effectiveness research, 2026) Systematic review Oral pre-exposure prophylaxis initiation, continuation and adherence among pregnant and postpartum women receiving antenatal and postnatal care: a systematic review (Journal of the International AIDS Society, 2025) Clinical trial publication Cardiometabolic impact of dolutegravir as second-line therapy: secondary analysis of a randomized controlled trial (AIDS (London, England), 2026) Clinical trial publication Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial (The lancet. HIV, 2026) Clinical trial publication Evaluating B/F/TAF at the first HIV-specialist appointment in antiretroviral naive persons living with HIV: the bifast study (BMC infectious diseases, 2026) Clinical trial publication Safety, acceptability, and adherence to dapivirine vaginal ring and oral pre-exposure prophylaxis for HIV prevention in the second trimester of pregnancy: a multicountry, open-label, phase 3b randomised trial (The lancet. HIV, 2026) Clinical trial publication Short-cycle three-day-per-week efavirenz/emtricitabine/tenofovir disoproxil fumarate therapy: a seven-year extension study (The Journal of antimicrobial chemotherapy, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
ENFUVIRTIDE	Biologic	Approved	Strong	100	8 trials 2 Meta-analysis 105 Trial pubs 64 RCT View evidence Registry trials NCT00051831 — Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults (COMPLETED) NA NCT00488059 — A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients (TERMINATED) PHASE4 NCT02302547 — Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (COMPLETED) PHASE3 NCT00925756 — CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery (COMPLETED) PHASE4 NCT00192660 — HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001) (COMPLETED) PHASE4 NCT02569502 — A Study of Enfuvirtide (Fuzeon) in Patients With Advanced Human Immunodeficiency Virus-1 (HIV-1) Infection (COMPLETED) PHASE4 NCT00326963 — BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. (COMPLETED) PHASE4 NCT00050856 — Fuzeon (Enfuvirtide) Early Access Program for Patients With HIV-1 Infection (COMPLETED) PHASE3 Published literature Meta-analysis Efficacy of new antiretroviral drugs in treatment-experienced HIV-infected patients: a systematic review and meta-analysis of recent randomized controlled trials (HIV medicine, 2012) Meta-analysis Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations (HIV clinical trials, 2006) Clinical trial publication Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study (The lancet. HIV, 2020) Clinical trial publication Metabolic, mitochondrial, renal and hepatic safety of enfuvirtide and raltegravir antiretroviral administration: Randomized crossover clinical trial in healthy volunteers (PloS one, 2019) Clinical trial publication Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial (AIDS research and therapy, 2016) Clinical trial publication Assessment of etravirine resistance in HIV-1-infected paediatric patients using population and deep sequencing: final results of the PIANO study (Antiviral therapy, 2016) Clinical trial publication Safety and Efficacy of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Adults Undergoing Autologous or Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies (Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016) Randomized controlled trial Pharmacokinetics of sifuvirtide in treatment-naive and treatment-experienced HIV-infected patients (Journal of pharmaceutical sciences, 2014) Randomized controlled trial Decreases in inflammatory and coagulation biomarkers levels in HIV-infected patients switching from enfuvirtide to raltegravir: ANRS 138 substudy (The Journal of infectious diseases, 2013) Randomized controlled trial Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo) (Antimicrobial agents and chemotherapy, 2013) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
ETRAVIRINE	Small molecule	Approved	Strong	100	8 trials 2 Cochrane 3 Meta-analysis 79 Trial pubs 38 RCT View evidence Registry trials NCT01118871 — The First Failure Study (TERMINATED) PHASE4 NCT02302547 — Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (COMPLETED) PHASE3 NCT00925756 — CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery (COMPLETED) PHASE4 NCT01422330 — A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients (COMPLETED) PHASE4 NCT01034917 — Switching From Protease Inhibitor (PI) to Etravirine in HIV-1 Infected Subjects With Viremia Suppression (COMPLETED) PHASE3 NCT00782301 — Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients (WITHDRAWN) PHASE4 NCT00531323 — TMC 125 Blood Levels Study (COMPLETED) PHASE1 NCT00903682 — A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients (COMPLETED) PHASE2 Published literature Cochrane review Second- and Third-line Antiretroviral Therapy for Children and Adolescents: A Scoping Review (The Pediatric infectious disease journal, 2017) Cochrane review Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults (Journal of infection and public health, 2015) Meta-analysis Interactions of Antiretroviral Drugs with Food, Beverages, Dietary Supplements, and Alcohol: A Systematic Review and Meta-analyses (AIDS and behavior, 2023) Meta-analysis Efficacy of new antiretroviral drugs in treatment-experienced HIV-infected patients: a systematic review and meta-analysis of recent randomized controlled trials (HIV medicine, 2012) Meta-analysis Modelling-based prediction of clinical benefits from etravirine in the TMC125-C223 trial (HIV clinical trials, 2007) Systematic review Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV: A Systematic Review (Clinical pharmacokinetics, 2023) Clinical trial publication Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087) (Clinical cancer research : an official journal of the American Association for Cancer Research, 2023) Clinical trial publication Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen (The Journal of antimicrobial chemotherapy, 2021) Clinical trial publication Characterization of viral rebounds on dual etravirine/raltegravir maintenance therapy (ANRS-163 ETRAL trial) (The Journal of antimicrobial chemotherapy, 2020) Clinical trial publication Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study (The lancet. HIV, 2019) Clinical trial publication Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL Study (Pharmacotherapy, 2019) Randomized controlled trial Efficacy and safety of lersivirine versus etravirine for the treatment of HIV-1 infection in patients with prior non-nucleoside reverse transcriptase inhibitor (NNRTI) use and evidence of NNRTI resistance: a randomized phase 2B trial (HIV clinical trials, 2014) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
FOSAMPRENAVIR CALCIUM	Small molecule	Approved	Strong	100	8 trials View evidence Registry trials NCT01054586 — Fosamprenavir in Pts With Hepatic Impairment (COMPLETED) NCT00089583 — 48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection (COMPLETED) PHASE2 NCT02302547 — Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (COMPLETED) PHASE3 NCT00966329 — Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects (COMPLETED) PHASE4 NCT00148785 — A Pharmacokinetic (PK) Study of a Combination of Indinavir, Ritonavir, and Amprenavir (COMPLETED) PHASE4 NCT00242840 — Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir) (COMPLETED) PHASE3 NCT00122603 — Dual Boosted Protease Inhibitor Regimens Without Any Additional Antiretroviral Therapy in HIV-1 Infected Patients (ANRS127) (COMPLETED) PHASE2 NCT01054638 — HIV Treatment and CVD Events (COMPLETED) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
IBALIZUMAB	Biologic	Approved	Strong	100	8 trials 4 Trial pubs 3 RCT View evidence Registry trials NCT01292174 — Safety Study of Ibalizumab Subcutaneous Injection in Healthy Volunteers (COMPLETED) PHASE1 NCT00784147 — Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1 (COMPLETED) PHASE2 NCT02707861 — Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1 (COMPLETED) PHASE3 NCT05890963 — 10E8.4/iMab Bispecific Antibody and VRC07-523LS Monoclonal Antibody in HIV-infected Adults (ACTIVE_NOT_RECRUITING) PHASE1 NCT00089700 — TNX-355 With Optimized Background Therapy (OBT) in Treatment-Experienced Subjects With HIV-1 (UNKNOWN) PHASE2 NCT02475629 — Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV (COMPLETED) PHASE3 NCT02028819 — Compassionate Use of Ibalizumab for the Treatment of HIV Infection (NO_LONGER_AVAILABLE) NCT03913195 — Study of the Safety of Trogarzo™ Administered as an Undiluted "IV Push" or an Intramuscular Injection (COMPLETED) PHASE3 Published literature Systematic review Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV: A Systematic Review (Clinical pharmacokinetics, 2023) Systematic review Indirect Treatment Comparisons of Lenacapavir Plus Optimized Background Regimen Versus Other Treatments for Multidrug-Resistant Human Immunodeficiency Virus (Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2023) Systematic review Comparative Efficacy and Safety of Fostemsavir in Heavily Treatment-Experienced People With HIV-1 (Clinical therapeutics, 2022) Clinical trial publication Efficacy and Safety of 2 Fixed Doses of Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced HIV-Positive Individuals (Journal of acquired immune deficiency syndromes (1999), 2024) Clinical trial publication Efficacy, Pharmacokinetics, and Safety Over 48 Weeks With Ibalizumab-Based Therapy in Treatment-Experienced Adults Infected With HIV-1: A Phase 2a Study (Journal of acquired immune deficiency syndromes (1999), 2021) Clinical trial publication Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1 (The New England journal of medicine, 2018) Clinical trial publication Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults (Antimicrobial agents and chemotherapy, 2009) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
LAMIVUDINE	Small molecule	Approved	Strong	100	8 trials 30 Cochrane 49 Meta-analysis 1087 Trial pubs 750 RCT View evidence Registry trials NCT00000875 — Controlled Clinical Trial of Antiviral Cytotoxic T Lymphocyte (CTL) Infusion Following Combination Antiretroviral Drug Therapy for Asymptomatic HIV-1 Infection (TERMINATED) NA NCT01511237 — Perinatal Antiretroviral Intensification for PMTCT of HIV in Late Comers (COMPLETED) PHASE3 NCT00087945 — Blood Levels of Abacavir in HIV Infected Adolescents (COMPLETED) NA NCT03311945 — Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM (COMPLETED) PHASE3 NCT00978237 — Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients (COMPLETED) PHASE4 NCT05979311 — A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy (ACTIVE_NOT_RECRUITING) PHASE3 NCT00004998 — Safety and Effectiveness of a New Anti-HIV Drug (AG1549) in Combination With Other Anti-HIV Drugs in HIV-Infected Patients (SUSPENDED) PHASE2 NCT00000887 — A Study to Evaluate the Safety and Tolerance of Nelfinavir (NFV) Given With Zidovudine (ZDV) and Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants (COMPLETED) PHASE1 Published literature Cochrane review Virological outcomes of dolutegravir-based versus other antiretroviral regimens in people living with HIV: A systematic review and meta-analysis (BMC infectious diseases, 2026) Cochrane review Comparison of treatment-emergent resistance-associated mutations and discontinuation due to adverse events among integrase strand transfer inhibitor-based single-tablet regimens and cabotegravir + rilpivirine for the treatment of virologically suppressed people with HIV: A systematic literature review and network meta-analysis (HIV medicine, 2025) Cochrane review A Systematical Review on ART Use in HTLV Infection: Clinical, Virological, and Immunological Outcomes (Pathogens (Basel, Switzerland), 2024) Cochrane review Comparison of safety and effectiveness of antiretroviral therapy regimens among pregnant women living with HIV at preconception or during pregnancy: a systematic review and network meta-analysis of randomized trials (BMC infectious diseases, 2024) Cochrane review Antivirals for prevention of hepatitis B virus mother-to-child transmission in human immunodeficiency virus positive pregnant women co-infected with hepatitis B virus (The Cochrane database of systematic reviews, 2023) Meta-analysis Association of nucleoside reverse transcriptase inhibitors with adverse perinatal outcomes in pregnant women living with HIV: systematic review and meta-analysis (Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2025) Meta-analysis Risk of viral failure after simplification therapy without using integrase inhibitors compared with maintenance of triple antiretroviral therapy: A systematic review and meta-analysis (The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2024) Systematic review Dolutegravir + lamivudine effectiveness and tolerability in real-world cohorts with HIV-1 across Asia and South America: A systematic literature review (Medicine, 2025) Clinical trial publication Exposure-response modeling of QTc interval and creatine kinase-MB in healthy people and treatment-naïve adults living with HIV-1 treated with ainuovirine monotherapy or combined with lamivudine and tenofovir DF (European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2026) Clinical trial publication Efficacy and safety of short-cycle, dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a multicentre, open-label, randomised, parallel, two-arm, non-inferiority trial (The lancet. HIV, 2026) Clinical trial publication Comparative evaluation of human T lymphocytes in HIV patients treated with lamivudine + zidovudine combined with nevirapine versus efavirenz (Medicine, 2026) Clinical trial publication Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial (Nature communications, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
LOPINAVIR	Small molecule	Approved	Strong	100	8 trials 12 Cochrane 30 Meta-analysis 525 Trial pubs 342 RCT View evidence Registry trials NCT00978237 — Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients (COMPLETED) PHASE4 NCT01296152 — Pharmacokinetic Interactions Between DMPA and LPV/r Among HIV-Infected Women (COMPLETED) PHASE2 NCT05850728 — First in Human Study of TLC-ART 101 (ACTU 2001) (COMPLETED) PHASE1 NCT00585793 — Relationship Between HIV-1 Subtype and ARV Response (COMPLETED) NCT01533272 — Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1:FOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC (MARAVI-PEP) (COMPLETED) PHASE4 NCT02369965 — Test Albuvirtide in Experienced Patients (COMPLETED) PHASE3 NCT00099632 — Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During Pregnancy (COMPLETED) PHASE2 NCT00437476 — Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Antiretroviral (ARV) Naive Patients Starting Treatment With Anti-HCV Therapy (UNKNOWN) PHASE3 Published literature Cochrane review Effectiveness and safety of darunavir and lopinavir for treating children and adolescents living with HIV: a systematic review (BMC infectious diseases, 2026) Cochrane review Efficacy of artemisinin-based combination therapy (ACT) in people living with HIV (PLHIV) diagnosed with uncomplicated Plasmodium falciparum malaria in Africa: a WWARN systematic review (Malaria journal, 2025) Cochrane review Antivirals for prevention of hepatitis B virus mother-to-child transmission in human immunodeficiency virus positive pregnant women co-infected with hepatitis B virus (The Cochrane database of systematic reviews, 2023) Cochrane review Adverse perinatal outcomes associated with antiretroviral therapy regimens: systematic review and network meta-analysis (AIDS (London, England), 2020) Cochrane review Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysis (The lancet. HIV, 2017) Meta-analysis Adverse perinatal outcomes associated with different classes of antiretroviral drugs in pregnant women with HIV (AIDS (London, England), 2025) Meta-analysis Interactions of Antiretroviral Drugs with Food, Beverages, Dietary Supplements, and Alcohol: A Systematic Review and Meta-analyses (AIDS and behavior, 2023) Meta-analysis Atazanavir / ritonavir versus Lopinavir / ritonavir-based combined antiretroviral therapy (cART) for HIV-1 infection: a systematic review and meta-analysis (African health sciences, 2020) Meta-analysis Network meta-analysis of post-exposure prophylaxis randomized clinical trials (HIV medicine, 2021) Systematic review Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV, Part II: Drugs Licensed Before 2005 (Clinical pharmacokinetics, 2024) Clinical trial publication Weight gain, body composition, and metabolic parameters of dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: an ancillary analysis of the ODYSSEY trial (The Lancet. Child & adolescent health, 2026) Clinical trial publication Pharmacokinetics of Dexamethasone in Tuberculous Meningitis (Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
MARAVIROC	Small molecule	Approved	Strong	100	8 trials 5 Cochrane 11 Meta-analysis 124 Trial pubs 90 RCT View evidence Registry trials NCT00821535 — Investigation Of Safety And Pharmacokinetics Following A Single Oral Dose Of 300 Mg Maraviroc In Healthy Male Japanese Volunteers (COMPLETED) PHASE1 NCT01533272 — Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1:FOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC (MARAVI-PEP) (COMPLETED) PHASE4 NCT00665561 — Prospective Observational Epidemiologic Study of Maraviroc's Safety (COMPLETED) NCT03708861 — Pharmacokinetics of Maraviroc and Boosted Atazanavir Dual Regimen in Stable HIV-infected Patients (WITHDRAWN) PHASE3 NCT00992654 — A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India (NO_LONGER_AVAILABLE) NCT02961829 — Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure (COMPLETED) NA NCT02302547 — Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (COMPLETED) PHASE3 NCT01204905 — R5 Integrase Study in HIV-1 Naive Patients (COMPLETED) NA Published literature Cochrane review Effectiveness of interventions on cognitive decline risk for people living with HIV on antiretroviral therapy: a systematic review (The lancet. Healthy longevity, 2026) Cochrane review Risk of failure in dual therapy versus triple therapy in naïve HIV patients: a systematic review and meta-analysis (Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2021) Cochrane review Atrial fibrillation and human immunodeficiency virus type-1 infection: a systematic review. Implications for anticoagulant and antiarrhythmic therapy (British journal of clinical pharmacology, 2019) Cochrane review Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis (The lancet. HIV, 2016) Cochrane review Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (PloS one, 2015) Meta-analysis Risk of viral failure after simplification therapy without using integrase inhibitors compared with maintenance of triple antiretroviral therapy: A systematic review and meta-analysis (The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2024) Meta-analysis Network meta-analysis of post-exposure prophylaxis randomized clinical trials (HIV medicine, 2021) Meta-analysis HIV-1 subtype C predicted co-receptor tropism in Africa: an individual sequence level meta-analysis (AIDS research and therapy, 2020) Systematic review Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV: A Systematic Review (Clinical pharmacokinetics, 2023) Clinical trial publication Switching to Low Neurotoxic Antiretrovirals to Improve Neurocognition Among People Living With HIV-1-Associated Neurocognitive Disorder: The MARAND-X Randomized Clinical Trial (Journal of acquired immune deficiency syndromes (1999), 2024) Clinical trial publication Pharmacologic Drug Detection and Self-Reported Adherence in the HPTN069/ACTG5305 Phase II PrEP Trial (AIDS and behavior, 2024) Clinical trial publication MAVMET trial: maraviroc and/or metformin for metabolic dysfunction associated fatty liver disease in adults with suppressed HIV (AIDS (London, England), 2024) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
NEVIRAPINE	Small molecule	Approved	Strong	100	8 trials 29 Cochrane 50 Meta-analysis 604 Trial pubs 393 RCT View evidence Registry trials NCT01511237 — Perinatal Antiretroviral Intensification for PMTCT of HIV in Late Comers (COMPLETED) PHASE3 NCT00001135 — A Study of Nevirapine to Prevent HIV Transmission From Mothers to Their Infants (COMPLETED) PHASE3 NCT00703898 — Durability of Nevirapine-Based Antiretroviral Regimen (COMPLETED) PHASE4 NCT00986063 — Genotype Based Personalized Prescription of Nevirapine (COMPLETED) PHASE4 NCT00099632 — Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During Pregnancy (COMPLETED) PHASE2 NCT03088410 — Study of HIV-Infected and Uninfected Pregnant Woman/Child Dyads in Gaborone, Botswana (COMPLETED) PHASE4 NCT01728961 — Pharmacology of Antimalarial Therapy With or Without Antiretroviral Therapy (TERMINATED) PHASE4 NCT00427297 — Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya (TERMINATED) PHASE3 Published literature Cochrane review Insights from systematic reviews (2019-2024) and drug interaction database analysis in people with HIV and comorbidities (International journal of STD & AIDS, 2026) Cochrane review Efficacy of artemisinin-based combination therapy (ACT) in people living with HIV (PLHIV) diagnosed with uncomplicated Plasmodium falciparum malaria in Africa: a WWARN systematic review (Malaria journal, 2025) Cochrane review Associations between human leukocyte antigen polymorphisms and hypersensitivity to antiretroviral therapy in patients with human immunodeficiency virus: a meta-analysis (BMC infectious diseases, 2019) Cochrane review Comparative safety and effectiveness of perinatal antiretroviral therapies for HIV-infected women and their children: Systematic review and network meta-analysis including different study designs (PloS one, 2018) Cochrane review Optimal Antiretroviral Prophylaxis in Infants at High Risk of Acquiring HIV: A Systematic Review (The Pediatric infectious disease journal, 2018) Meta-analysis Burden of virologic failure, and its determinants among HIV positive children in East Africa: a systematic review and meta-analysis (African health sciences, 2024) Meta-analysis Epidemiology of Antiretroviral Therapy Related Adverse Drug Reactions and its Predictors Among Patients with Human Immunodeficiency Virus/AIDS in Ethiopia: A Systematic Review and Meta-analysis (Journal of the International Association of Providers of AIDS Care, 2025) Meta-analysis Magnitude and characteristics of unsuppressed HIV viral load in children and adolescents on antiretroviral therapy in sub-Saharan Africa: a systematic review and meta-analysis (The lancet. HIV, 2025) Meta-analysis Prevalence and predictors of virological failure among the people living with HIV on antiretroviral treatment in East Africa: evidence from a systematic review with meta-analysis and meta-regression of published studies from 2016 to 2023 (HIV research & clinical practice, 2025) Meta-analysis Risk of viral failure after simplification therapy without using integrase inhibitors compared with maintenance of triple antiretroviral therapy: A systematic review and meta-analysis (The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2024) Clinical trial publication Comparative evaluation of human T lymphocytes in HIV patients treated with lamivudine + zidovudine combined with nevirapine versus efavirenz (Medicine, 2026) Clinical trial publication Regional Variations of Rates and Determinants of Drug Resistance Mutations in People Failing First-line Therapy for HIV-1: A Substudy from the D2EFT Phase 3b/4 Clinical Trial (Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
RALTEGRAVIR POTASSIUM	Small molecule	Approved	Strong	100	8 trials View evidence Registry trials NCT03311945 — Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM (COMPLETED) PHASE3 NCT00672932 — Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 Patients (COMPLETED) NA NCT00488059 — A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients (TERMINATED) PHASE4 NCT00515827 — Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load (COMPLETED) PHASE2 NCT01854762 — Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV Infection (TERMINATED) PHASE2, PHASE3 NCT00772551 — Raltegravir and Ezetimibe PK Study (COMPLETED) PHASE1 NCT02708342 — Observational, Retrospective Analysis in HIV-1 Infected Patients. (ORASWIRAL) (COMPLETED) NCT00764946 — A Study of Raltegravir in a Diverse Cohort of HIV-Infected Patients (0518-055) (COMPLETED) PHASE3 CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
RIFABUTIN	Small molecule	Approved	Strong	100	8 trials 4 Cochrane 3 Meta-analysis 65 Trial pubs 45 RCT View evidence Registry trials NCT01894776 — A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of Maraviroc (COMPLETED) PHASE1 NCT00018083 — Intensive Pharmacokinetics of the Nelfinavir-Rifabutin Interaction in Patients With HIV-Related Tuberculosis Treated With a Rifabutin-Based Regimen (UNKNOWN) NA NCT00001047 — Study of Four Different Treatment Approaches for Patients Who Have Mycobacterium Avium Complex Disease (MAC) Plus AIDS (COMPLETED) PHASE3 NCT00001058 — A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients With AIDS (COMPLETED) PHASE2 NCT00646776 — Drug Interaction Study (COMPLETED) PHASE1 NCT00023400 — TBTC Study 23B:Intensive PK of the Nelfinavir Rifabutin Interaction in Patients With HIV-TB (COMPLETED) PHASE4 NCT00000877 — Study of How Indinavir (an Anti-HIV Drug) and Rifabutin (a Drug Used to Treat MAC, an HIV-Associated Disease) Interact in HIV-Positive and HIV-Negative Adults (COMPLETED) PHASE1 NCT00002267 — Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial (COMPLETED) NA Published literature Cochrane review Interventions for the prevention of mycobacterium avium complex in adults and children with HIV (The Cochrane database of systematic reviews, 2013) Cochrane review HIV: primary and secondary prophylaxis for opportunistic infections (BMJ clinical evidence, 2010) Cochrane review HIV: treating tuberculosis (BMJ clinical evidence, 2009) Cochrane review Tuberculosis in people with HIV (BMJ clinical evidence, 2007) Meta-analysis Comparing clinical outcomes of antibiotics for treating Mycobacterium avium complex infection in adults with HIV: a systematic review and network meta-analysis (AIDS (London, England), 2026) Meta-analysis Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis (Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010) Systematic review Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review (Clinical pharmacokinetics, 2021) Clinical trial publication Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus-Tuberculosis Coinfection (Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021) Clinical trial publication Effect of SLCO1B1 Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis (Antimicrobial agents and chemotherapy, 2016) Clinical trial publication Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy (BMC pharmacology & toxicology, 2014) Clinical trial publication Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir (The Journal of antimicrobial chemotherapy, 2015) Clinical trial publication Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam (PloS one, 2014) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
RITONAVIR	Small molecule	Approved	Strong	100	8 trials 21 Cochrane 54 Meta-analysis 1235 Trial pubs 744 RCT View evidence Registry trials NCT00476502 — Study of Genetic Polymorphisms in Thai HIV-1 Infected Patients on SQV/r (COMPLETED) NCT00978237 — Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients (COMPLETED) PHASE4 NCT02289495 — A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects (TERMINATED) PHASE1 NCT01296152 — Pharmacokinetic Interactions Between DMPA and LPV/r Among HIV-Infected Women (COMPLETED) PHASE2 NCT05850728 — First in Human Study of TLC-ART 101 (ACTU 2001) (COMPLETED) PHASE1 NCT00585793 — Relationship Between HIV-1 Subtype and ARV Response (COMPLETED) NCT01118871 — The First Failure Study (TERMINATED) PHASE4 NCT01533272 — Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1:FOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC (MARAVI-PEP) (COMPLETED) PHASE4 Published literature Cochrane review Effectiveness and safety of darunavir and lopinavir for treating children and adolescents living with HIV: a systematic review (BMC infectious diseases, 2026) Cochrane review Insights from systematic reviews (2019-2024) and drug interaction database analysis in people with HIV and comorbidities (International journal of STD & AIDS, 2026) Cochrane review Efficacy of artemisinin-based combination therapy (ACT) in people living with HIV (PLHIV) diagnosed with uncomplicated Plasmodium falciparum malaria in Africa: a WWARN systematic review (Malaria journal, 2025) Cochrane review Antivirals for prevention of hepatitis B virus mother-to-child transmission in human immunodeficiency virus positive pregnant women co-infected with hepatitis B virus (The Cochrane database of systematic reviews, 2023) Cochrane review The effect of protease inhibitors-based antiretroviral therapy on serum/plasma interleukin-6 levels among PLHIV: a systematic review and meta-analysis (Journal of medical virology, 2022) Meta-analysis Adverse perinatal outcomes associated with different classes of antiretroviral drugs in pregnant women with HIV (AIDS (London, England), 2025) Meta-analysis Interactions of Antiretroviral Drugs with Food, Beverages, Dietary Supplements, and Alcohol: A Systematic Review and Meta-analyses (AIDS and behavior, 2023) Meta-analysis Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis (BMC infectious diseases, 2021) Meta-analysis Atazanavir / ritonavir versus Lopinavir / ritonavir-based combined antiretroviral therapy (cART) for HIV-1 infection: a systematic review and meta-analysis (African health sciences, 2020) Systematic review Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV, Part II: Drugs Licensed Before 2005 (Clinical pharmacokinetics, 2024) Clinical trial publication The dolutegravir failure cohort: A multi-country longitudinal cohort with a randomised clinical trial of continued dolutegravir versus switch to darunavir in people with viraemia while on dolutegravir in Sub-Saharan Africa (The Ndovu Study) protocol (PloS one, 2026) Clinical trial publication Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial (Nature communications, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
SAQUINAVIR	Small molecule	Approved	Strong	100	8 trials 1 Cochrane 4 Meta-analysis 250 Trial pubs 123 RCT View evidence Registry trials NCT00476502 — Study of Genetic Polymorphisms in Thai HIV-1 Infected Patients on SQV/r (COMPLETED) NCT00002334 — A Study of Zidovudine (AZT) Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients With Little or No Previous Treatment (COMPLETED) PHASE3 NCT00002367 — A Study of Saquinavir Soft Gelatin Capsules Plus Zidovudine Plus Lamivudine in the Treatment of HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs (COMPLETED) PHASE3 NCT00051831 — Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults (COMPLETED) NA NCT02302547 — Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (COMPLETED) PHASE3 NCT02239835 — Tipranavir and Ritonavir vs. Saquinavir and Ritonavir Used With Two Nucleoside Reverse Transcriptase Inhibitors in Single Protease Inhibitor-experienced HIV-1 Patients (TERMINATED) PHASE2 NCT00000848 — The Anti-HIV Effects of Saquinavir Soft Gelatin Capsules Versus Indinavir in Patients Who Have Used Saquinavir Hard Gelatin Capsules for One Year (COMPLETED) PHASE2 NCT00192608 — A 48-Week, Randomised, Study to Describe the Pharmacokinetic Profile and Durability of Atazanavir-Saquinavir-Ritonavir Once Daily and Describe the Pharmacokinetic Profile of Saquinavir-Ritonavir Using Saquinavir 500mg Formulation: the ASK-500 Study (COMPLETED) NA Published literature Cochrane review Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV (The Cochrane database of systematic reviews, 2013) Meta-analysis Interactions of Antiretroviral Drugs with Food, Beverages, Dietary Supplements, and Alcohol: A Systematic Review and Meta-analyses (AIDS and behavior, 2023) Meta-analysis Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels (HIV clinical trials, 2009) Meta-analysis Fosamprenavir clinical study meta-analysis in ART-naïve subjects: rare occurrence of virologic failure and selection of protease-associated mutations (HIV clinical trials, 2006) Systematic review Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review (Clinical pharmacokinetics, 2021) Systematic review Protecting the fetus against HIV infection: a systematic review of placental transfer of antiretrovirals (Clinical pharmacokinetics, 2014) Systematic review HIV-1 protease inhibitors. A review for clinicians (JAMA, 1997) Clinical trial publication Improved adipose tissue function with initiation of protease inhibitor-only ART (The Journal of antimicrobial chemotherapy, 2016) Clinical trial publication Effect of a modified saquinavir/ritonavir dosing regimen with lower dose lead-in phase on QTc interval, pharmacokinetics, antiviral activity and safety in treatment-naïve HIV-1-infected patients (Drugs in R&D, 2015) Clinical trial publication Provirus activation plus CD59 blockage triggers antibody-dependent complement-mediated lysis of latently HIV-1-infected cells (Journal of immunology (Baltimore, Md. : 1950), 2014) Clinical trial publication Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146 (Therapeutic drug monitoring, 2013) Clinical trial publication Effectiveness and safety of saquinavir/ritonavir in HIV-infected pregnant women: INEMA cohort (Medecine et maladies infectieuses, 2012) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
SOMATROPIN	Biologic	Approved	Strong	100	8 trials View evidence Registry trials NCT02196831 — Tesamorelin Effects on Liver Fat and Histology in HIV (COMPLETED) NA NCT03826160 — Growth Hormone Dynamics and Cardiac Steatosis in HIV (COMPLETED) NCT00287677 — Induction and Expansion of T Cell Repertoire Using Growth Hormone and Vaccination in HIV-1 Infected Patients (COMPLETED) PHASE4 NCT00608023 — TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy (COMPLETED) PHASE3 NCT00119769 — The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients (COMPLETED) PHASE4 NCT00286689 — Effects of Growth Hormone in Chronically Ill Children (WITHDRAWN) NA NCT02012556 — Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients (COMPLETED) PHASE1 NCT00489528 — Growth Hormone in the Treatment of HIV-Associated Wasting (COMPLETED) PHASE3 CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
TENOFOVIR ALAFENAMIDE FUMARATE	Small molecule	Approved	Strong	100	—	Open Targets, ChEMBL	ChEMBL Open Targets
TENOFOVIR DISOPROXIL FUMARATE	Small molecule	Approved	Strong	100	8 trials 22 Cochrane 37 Meta-analysis 520 Trial pubs 413 RCT View evidence Registry trials NCT01118871 — The First Failure Study (TERMINATED) PHASE4 NCT04898699 — IPrEP Men's Study: Expanding the Reach of Prevention for Men in Kisumu, Kenya (COMPLETED) EARLY_PHASE1 NCT05492565 — Seville Cohort of People at Substantial Risk for HIV Infection on Pre-exposure Prophylaxis (ENROLLING_BY_INVITATION) NCT00051831 — Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults (COMPLETED) NA NCT06766331 — Integrated Care Versus Usual Care for Opioid Use Disorder and Infectious Diseases in Veterans (NOT_YET_RECRUITING) NA NCT00099632 — Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During Pregnancy (COMPLETED) PHASE2 NCT01778413 — Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine (COMPLETED) PHASE4 NCT03708861 — Pharmacokinetics of Maraviroc and Boosted Atazanavir Dual Regimen in Stable HIV-infected Patients (WITHDRAWN) PHASE3 Published literature Cochrane review Lenacapavir as pre-exposure prophylaxis for HIV prevention (The Cochrane database of systematic reviews, 2026) Cochrane review Population Pharmacokinetic Simulations for Dose Optimization of Tenofovir Disoproxil Fumarate in HIV-Infected Patients with Moderate-to-Severe Renal Impairment (Journal of clinical pharmacology, 2025) Cochrane review Risk of dyslipidaemia in people living with HIV who are taking tenofovir alafenamide: a systematic review and meta-analysis (Journal of the International AIDS Society, 2024) Cochrane review Adherence and HIV Protection Thresholds for Emtricitabine and Tenofovir Disoproxil Fumarate Preexposure Prophylaxis among Cisgender Women: A Systematic Review (Current HIV/AIDS reports, 2024) Cochrane review Low clinical impact of HIV drug resistance mutations in oral pre-exposure prophylaxis: a systematic review and meta-analysis (AIDS research and therapy, 2024) Meta-analysis Chronic kidney disease among people living with HIV on TDF based regimen: A systematic review and meta-analysis (PloS one, 2025) Meta-analysis Association of nucleoside reverse transcriptase inhibitors with adverse perinatal outcomes in pregnant women living with HIV: systematic review and meta-analysis (Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2025) Meta-analysis Neuropsychiatric adverse events in tenofovir disoproxil fumarate- and tenofovir alafenamide-based HIV therapy and prophylaxis: a systematic review and meta‑analysis (Polish archives of internal medicine, 2024) Systematic review Performance of Adherence Measures for Oral, Tenofovir-Based HIV Pre-Exposure Prophylaxis: A Systematic Review (AIDS and behavior, 2025) Systematic review Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV, Part II: Drugs Licensed Before 2005 (Clinical pharmacokinetics, 2024) Clinical trial publication Exposure-response modeling of QTc interval and creatine kinase-MB in healthy people and treatment-naïve adults living with HIV-1 treated with ainuovirine monotherapy or combined with lamivudine and tenofovir DF (European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2026) Clinical trial publication Efficacy and safety of short-cycle, dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a multicentre, open-label, randomised, parallel, two-arm, non-inferiority trial (The lancet. HIV, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
TIPRANAVIR	Small molecule	Approved	Strong	100	8 trials 1 Cochrane 3 Meta-analysis 30 Trial pubs 25 RCT View evidence Registry trials NCT02302547 — Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (COMPLETED) PHASE3 NCT02239835 — Tipranavir and Ritonavir vs. Saquinavir and Ritonavir Used With Two Nucleoside Reverse Transcriptase Inhibitors in Single Protease Inhibitor-experienced HIV-1 Patients (TERMINATED) PHASE2 NCT00966329 — Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects (COMPLETED) PHASE4 NCT00925756 — CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery (COMPLETED) PHASE4 NCT00192660 — HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001) (COMPLETED) PHASE4 NCT02249130 — Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir (COMPLETED) PHASE2 NCT00056641 — Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients (COMPLETED) PHASE2 NCT02229760 — Effect of Steady State TPV/r on Intracellular Concentrations of Zidovudine and Carbovir for Patients With HIV (TERMINATED) PHASE1, PHASE2 Published literature Cochrane review Virologic response to tipranavir-ritonavir or darunavir-ritonavir based regimens in antiretroviral therapy experienced HIV-1 patients: a meta-analysis and meta-regression of randomized controlled clinical trials (PloS one, 2013) Meta-analysis Efficacy of new antiretroviral drugs in treatment-experienced HIV-infected patients: a systematic review and meta-analysis of recent randomized controlled trials (HIV medicine, 2012) Meta-analysis Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations (HIV clinical trials, 2006) Systematic review Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV, Part II: Drugs Licensed Before 2005 (Clinical pharmacokinetics, 2024) Systematic review Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV: A Systematic Review (Clinical pharmacokinetics, 2023) Clinical trial publication Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial (AIDS research and therapy, 2016) Clinical trial publication Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial (PloS one, 2016) Clinical trial publication Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race-ethnicity determine the degree of regimen complexity (HIV clinical trials, 2015) Clinical trial publication Efficacy and safety of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents: 5 years of experience (The Pediatric infectious disease journal, 2014) Clinical trial publication Boosted tipranavir versus darunavir in treatment-experienced patients: observational data from the randomized POTENT trial (Drugs in R&D, 2011) Randomized controlled trial Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial (The Journal of antimicrobial chemotherapy, 2011) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
ZIDOVUDINE	Small molecule	Approved	Strong	100	8 trials 37 Cochrane 48 Meta-analysis 1365 Trial pubs 880 RCT View evidence Registry trials NCT00000875 — Controlled Clinical Trial of Antiviral Cytotoxic T Lymphocyte (CTL) Infusion Following Combination Antiretroviral Drug Therapy for Asymptomatic HIV-1 Infection (TERMINATED) NA NCT01511237 — Perinatal Antiretroviral Intensification for PMTCT of HIV in Late Comers (COMPLETED) PHASE3 NCT00087945 — Blood Levels of Abacavir in HIV Infected Adolescents (COMPLETED) NA NCT00002334 — A Study of Zidovudine (AZT) Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients With Little or No Previous Treatment (COMPLETED) PHASE3 NCT00000734 — Evaluation of the Interaction Between High Dose Sulfamethoxazole/Trimethoprim and Zidovudine (COMPLETED) NA NCT00004998 — Safety and Effectiveness of a New Anti-HIV Drug (AG1549) in Combination With Other Anti-HIV Drugs in HIV-Infected Patients (SUSPENDED) PHASE2 NCT00000887 — A Study to Evaluate the Safety and Tolerance of Nelfinavir (NFV) Given With Zidovudine (ZDV) and Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants (COMPLETED) PHASE1 NCT01075152 — Cryptococcal Optimal ART Timing Trial (COMPLETED) PHASE4 Published literature Cochrane review Predictors of anemia among HIV-infected children in Ethiopia: systematic review and meta-analysis (Scientific reports, 2025) Cochrane review A Systematical Review on ART Use in HTLV Infection: Clinical, Virological, and Immunological Outcomes (Pathogens (Basel, Switzerland), 2024) Cochrane review Comparison of safety and effectiveness of antiretroviral therapy regimens among pregnant women living with HIV at preconception or during pregnancy: a systematic review and network meta-analysis of randomized trials (BMC infectious diseases, 2024) Cochrane review Antivirals for prevention of hepatitis B virus mother-to-child transmission in human immunodeficiency virus positive pregnant women co-infected with hepatitis B virus (The Cochrane database of systematic reviews, 2023) Cochrane review Does antiretroviral therapy cause congenital malformations? A systematic review and meta-analysis (Epidemiology and health, 2021) Meta-analysis Epidemiology of Antiretroviral Therapy Related Adverse Drug Reactions and its Predictors Among Patients with Human Immunodeficiency Virus/AIDS in Ethiopia: A Systematic Review and Meta-analysis (Journal of the International Association of Providers of AIDS Care, 2025) Meta-analysis Prevalence and risk factors of anemia among people living with HIV/AIDS in Southeast Asia: a systematic review and meta-analysis (BMC infectious diseases, 2025) Meta-analysis Association of nucleoside reverse transcriptase inhibitors with adverse perinatal outcomes in pregnant women living with HIV: systematic review and meta-analysis (Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2025) Systematic review Clinical Presentation, Etiology, and Outcomes of HIV-Associated Cardiomyopathy: A Systematic Review of Published Case Reports (Viruses, 2026) Clinical trial publication Acceptability of a Dolutegravir Oral Dispersible Film in Term Neonates Born to Mothers Living With HIV (Journal of the International AIDS Society, 2026) Clinical trial publication Comparative evaluation of human T lymphocytes in HIV patients treated with lamivudine + zidovudine combined with nevirapine versus efavirenz (Medicine, 2026) Clinical trial publication Regional Variations of Rates and Determinants of Drug Resistance Mutations in People Failing First-line Therapy for HIV-1: A Substudy from the D2EFT Phase 3b/4 Clinical Trial (Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
ALDESLEUKIN	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
NALTREXONE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
PEGINTERFERON ALFA-2A	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
RIBAVIRIN	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
BUPRENORPHINE	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
CHEMBL104	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201561	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL1410	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL70663	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL91	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHOLECALCIFEROL	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
ETHAMBUTOL HYDROCHLORIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
HEPATITIS B VIRUS HBSAG SURFACE PROTEIN ANTIGEN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INDINAVIR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LEVOFLOXACIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
NELFINAVIR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PYRAZINAMIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PYRIDOXINE HYDROCHLORIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
RIFAMPIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FOLIC ACID	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
LEVONORGESTREL	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
MINOCYCLINE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
PRAVASTATIN SODIUM	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ACYCLOVIR SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALENDRONIC ACID	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ATORVASTATIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BLEOMYCIN SULFATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CHEMBL1017	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL105318	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL109	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL109831	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201134	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201821	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1276308	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL131	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL135	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1617	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL2107384	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL2109042	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL2109047	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL2110727	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL2218911	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL25	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL38700	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL468	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL503	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL5314347	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL547	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL571987	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL573	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL672	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL692	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL717	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL76	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL848	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL98	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CYANOCOBALAMIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DOXORUBICIN HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EPIRUBICIN HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ERGOCALCIFEROL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ETONOGESTREL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ETOPOSIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FILGRASTIM	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GABAPENTIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GALANTAMINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GINSENG, AMERICAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INTERFERON	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INTERFERON ALFA	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INTERFERON ALFA-2B	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MECHLORETHAMINE HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MEGESTROL ACETATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OBEFAZIMOD	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PENTOXIFYLLINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PREDNISONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PYRIDOXINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SORIVUDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TESTOSTERONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TESTOSTERONE ENANTHATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VINBLASTINE SULFATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VINCRISTINE SULFATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ZALCITABINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CYCLOPHOSPHAMIDE	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
CHEMBL1064	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL1237022	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL1237026	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL1471	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL1751	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL2109446	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL3545347	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL393220	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL413	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL504	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL638	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL70927	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL843	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL932	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL964	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CP1-1189	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
EFINEPTAKIN ALFA	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
INTERLEUKIN-7	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
METHADONE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PEPTIDE T	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PRETOMANID	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RIFAPENTINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SILYBIN A	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE CRM197	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TIFUVIRTIDE	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TUCIDINOSTAT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ZINC ACETATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ZINC SULFATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
(+/-)NICOTINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ABACAVIR	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ATAZANAVIR	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ATEZOLIZUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
AZITHROMYCIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BICTEGRAVIR	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BOCEPREVIR	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CEFTRIAXONE SODIUM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DACLATASVIR	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DARUNAVIR	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DARUNAVIR ETHANOLATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DIDANOSINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DOLUTEGRAVIR	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DOLUTEGRAVIR SODIUM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ELASOMERAN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
EMTRICITABINE, (+/-)-	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
EPOETIN ALFA	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ETHAMBUTOL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ETHINYL ESTRADIOL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FALDAPREVIR	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FIPRAVIRIMAT	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FIPRAVIRIMAT MESYLATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FOMIVIRSEN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FOSTEMSAVIR TROMETHAMINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GANCICLOVIR	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GLECAPREVIR	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
INDINAVIR SULFATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ISONIAZID	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LENACAPAVIR	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LENACAPAVIR SODIUM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LERONLIMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MOXIFLOXACIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
NALOXONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
NELFINAVIR MESYLATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
NICOTINE	Small molecule	Preclinical	Emerging	15	8 trials 1 Cochrane 2 Meta-analysis 47 Trial pubs 45 RCT View evidence Registry trials NCT05162911 — Implementing Tobacco Use Treatment in HIV Clinics Vietnam (COMPLETED) NA NCT03904186 — Effectiveness of an Integrated Treatment to Address Smoking Cessation and Anxiety/ Depression in People Living With HIV (COMPLETED) NA NCT06880705 — The Trans-Led Care Study (RECRUITING) NA NCT05852860 — A Patient-Oriented Research Mentoring Program in Tobacco Dependence and Implementation Science Research (ACTIVE_NOT_RECRUITING) NA NCT01393301 — Integrated Treatment for Smoking Cessation & Anxiety in People With HIV (COMPLETED) NA NCT03224741 — Behavioral Economics Field Experiment in HIV Testing (COMPLETED) NA NCT02781090 — RCT of an Internet Cessation Program Plus Online Social Network for HIV+ Smokers (COMPLETED) NA NCT05030766 — Testing Integrative Smoking Cessation for HIV Patients (COMPLETED) PHASE4 Published literature Cochrane review Interventions for tobacco use cessation in people living with HIV (The Cochrane database of systematic reviews, 2024) Meta-analysis Meta-Analysis on Nicotine's Modulation of HIV-Associated Dementia (Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2022) Clinical trial publication Clinical Pharmacists, Medications, and Contingency Management for Targeting Smoking in HIV Clinics: A Randomized Clinical Trial (JAMA network open, 2026) Clinical trial publication Effectiveness of behavioural tobacco cessation interventions with and without pharmacotherapy among people living with HIV in Viet Nam: a three-arm pragmatic randomised controlled trial (The Lancet. Global health, 2026) Clinical trial publication Assessing the impact of nicotinic partial agonists compared to NRT on opioid and cigarette use: A secondary analysis investigating treatment outcomes for co-occurring nicotine and opioid use (Journal of substance use and addiction treatment, 2026) Clinical trial publication Population reach, feasibility and acceptability of digital therapeutics for smoking cessation among people living with HIV: Results of the Quitting Matters pilot trial (Drug and alcohol dependence, 2026) Clinical trial publication Galantamine for 12 weeks does not improve neurocognition or immune activation in ART-suppressed people with HIV (AIDS (London, England), 2026) CT.gov search · Cochrane · PubMed	Open Targets	ChEMBL Open Targets
ONDANSETRON	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PEMBROLIZUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PENICILLIN G POTASSIUM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PIBRENTASVIR	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
RALTEGRAVIR	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
RIFAMYCIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
RILPIVIRINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
RILPIVIRINE HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ROVAFOVIR ETALAFENAMIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ROVAFOVIR ETALAFENAMIDE CITRATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SAQUINAVIR MESYLATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SIMEPREVIR	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SOFOSBUVIR	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
STAVUDINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TELAPREVIR	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TENOFOVIR	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TENOFOVIR ALAFENAMIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TENOFOVIR DISOPROXIL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TENOFOVIR DISOPROXIL MALEATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TEROPAVIMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TOZINAMERAN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ZEGRUVIRIMAT	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ZEGRUVIRIMAT TOSYLATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ZINLIRVIMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
ACETAZOLAMIDE Repurposing via AP2A1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
AMPHETAMINE Repurposing via AP2A1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
APOMORPHINE HYDROCHLORIDE Repurposing via APOBEC3G	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BICALUTAMIDE Repurposing via AP2A1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CARBACHOL Repurposing via AP2A1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CEFOTETAN Repurposing via APOBEC3G	Small molecule	Approved	Strong	95	—	DGIdb	—
CIPROFLOXACIN Repurposing via AP2A1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CLOMIPRAMINE Repurposing via AP2A1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CYCLOPHOSPHAMIDE ANHYDROUS Repurposing via CCNK	Small molecule	Approved	Strong	95	—	DGIdb	—
DIAZEPAM Repurposing via AP2A1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing via AP2A1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIETHYLSTILBESTROL Repurposing via AP2A1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
EPIRUBICIN Repurposing via CCNK	Small molecule	Approved	Strong	95	—	DGIdb	—
EPIRUBICIN Repurposing via AP2A1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ETHOXZOLAMIDE Repurposing via AP2A1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
FLUMAZENIL Repurposing via AP2A1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
FLUOROURACIL Repurposing via CCNK	Small molecule	Approved	Strong	95	—	DGIdb	—
IMIPRAMINE Repurposing via AP2A1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDAPAMIDE Repurposing via AP2A1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDOMETHACIN Repurposing via AP2A1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ISOSORBIDE DINITRATE Repurposing via AP2A1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MAFENIDE Repurposing via AP2A1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MECAMYLAMINE Repurposing via AP2A1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHAZOLAMIDE Repurposing via AP2A1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHOXSALEN Repurposing via AP2A1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METOPROLOL Repurposing via AP2A1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MIANSERIN Repurposing via AP2A1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NALIDIXIC ACID Repurposing via AP2A1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NICOTINE Repurposing via AP2A1	Small molecule	Approved	Strong	95	8 trials 1 Cochrane 2 Meta-analysis 47 Trial pubs 45 RCT View evidence Registry trials NCT05162911 — Implementing Tobacco Use Treatment in HIV Clinics Vietnam (COMPLETED) NA NCT03904186 — Effectiveness of an Integrated Treatment to Address Smoking Cessation and Anxiety/ Depression in People Living With HIV (COMPLETED) NA NCT06880705 — The Trans-Led Care Study (RECRUITING) NA NCT05852860 — A Patient-Oriented Research Mentoring Program in Tobacco Dependence and Implementation Science Research (ACTIVE_NOT_RECRUITING) NA NCT01393301 — Integrated Treatment for Smoking Cessation & Anxiety in People With HIV (COMPLETED) NA NCT03224741 — Behavioral Economics Field Experiment in HIV Testing (COMPLETED) NA NCT02781090 — RCT of an Internet Cessation Program Plus Online Social Network for HIV+ Smokers (COMPLETED) NA NCT05030766 — Testing Integrative Smoking Cessation for HIV Patients (COMPLETED) PHASE4 Published literature Cochrane review Interventions for tobacco use cessation in people living with HIV (The Cochrane database of systematic reviews, 2024) Meta-analysis Meta-Analysis on Nicotine's Modulation of HIV-Associated Dementia (Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2022) Clinical trial publication Clinical Pharmacists, Medications, and Contingency Management for Targeting Smoking in HIV Clinics: A Randomized Clinical Trial (JAMA network open, 2026) Clinical trial publication Effectiveness of behavioural tobacco cessation interventions with and without pharmacotherapy among people living with HIV in Viet Nam: a three-arm pragmatic randomised controlled trial (The Lancet. Global health, 2026) Clinical trial publication Assessing the impact of nicotinic partial agonists compared to NRT on opioid and cigarette use: A secondary analysis investigating treatment outcomes for co-occurring nicotine and opioid use (Journal of substance use and addiction treatment, 2026) Clinical trial publication Population reach, feasibility and acceptability of digital therapeutics for smoking cessation among people living with HIV: Results of the Quitting Matters pilot trial (Drug and alcohol dependence, 2026) Clinical trial publication Galantamine for 12 weeks does not improve neurocognition or immune activation in ART-suppressed people with HIV (AIDS (London, England), 2026) CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
NORFLOXACIN Repurposing via AP2A1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
OFLOXACIN Repurposing via AP2A1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
PHENYTOIN Repurposing via AP2A1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
PRAZOSIN Repurposing via AP2A1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
SIROLIMUS Repurposing via AP2A1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
SULBACTAM Repurposing via AP2A1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TACROLIMUS ANHYDROUS Repurposing via AP2A1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TAZOBACTAM Repurposing via AP2A1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TROGLITAZONE Repurposing via AP2A1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DARAPLADIB Repurposing via AP2A1	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
FENRETINIDE Repurposing via AP2A1	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
ALPRENOLOL Repurposing via AP2A1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
AMIFLOXACIN Repurposing via AP2A1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
BROLAMFETAMINE Repurposing via AP2A1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
CARZENIDE Repurposing via AP2A1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIFLOXACIN Repurposing via AP2A1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIMECAMINE Repurposing via AP2A1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ELLAGIC ACID Repurposing via AP2A1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ENISOPROST Repurposing via AP2A1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FENCAMFAMIN Repurposing via AP2A1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FLEROXACIN Repurposing via AP2A1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
IDOXIFENE Repurposing via AP2A1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
LYSERGIDE Repurposing via AP2A1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
MERAFLOXACIN Repurposing via AP2A1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
TENAMFETAMINE Repurposing via AP2A1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ZIDAPAMIDE Repurposing via AP2A1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets

Natural Products

20 natural products with the same evidence schema as repurposed drugs — registry trials, PubMed literature, and reference links (pipeline-ranked)

Reference lookups: GreenMedInfo · Examine.com

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
Zinc Natural product Toxic Metals and Non-Communicable Diseases in HIV Population: A Systema… Effect of Zinc Supplementation vs Placebo on Mortality Risk and HIV Dis… The effect of selenium and zinc on CD4(+) count and opportunistic infec…	Nutraceutical	Approved	Emerging	19	8 trials 9 Meta-analysis View evidence Registry trials NCT02162797 — Zinc Supplementation Effect on Immune Recovery in HIV Patients (UNKNOWN) NA NCT02433743 — Impact of RUTF on Body Composition, Anemia and Zinc Status of PLWHA (COMPLETED) NA NCT03408899 — Evaluating the Safety and Pharmacokinetics of PC-1005 Administered Rectally to HIV-1 Seronegative Adults (COMPLETED) PHASE1 NCT05085834 — Zinc Effect on Inflammation and Cardiovascular Risk in HIV (COMPLETED) EARLY_PHASE1 NCT03404297 — Compression Therapy for Leg Ulcers and Kaposi Sarcoma in Western Kenya (COMPLETED) NA NCT02033109 — Safety, Pharmacokinetics and Acceptability of PC-1005 for Vaginal Use (COMPLETED) PHASE1 NCT00311298 — Nutrition, Diabetes and Pulmonary TB/HIV (COMPLETED) PHASE3 NCT01475227 — Atazanavir/Ritonavir and Zinc Pharmacokinetic Study (COMPLETED) PHASE4 CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	PubChem
Vitamin E Natural product Randomized controlled trial Impact of Nutrition Education on Nutrition Knowledge, Attitudes, Practi… Randomized controlled trial Vitamin A and D Deficiencies Associated With Incident Tuberculosis in H… Randomized controlled trial Effect of high-dose vs standard-dose multivitamin supplementation at th…	Nutraceutical	Phase III	Emerging	19	8 trials 3 Cochrane 2 Meta-analysis 13 RCT View evidence Registry trials NCT00037063 — A Study to See if Certain Antioxidants and Vitamins Will Keep Lactate Levels Down in Patients Taking Anti-HIV Drugs (WITHDRAWN) NA NCT03669133 — Vitamin E for NASH Treatment in HIV Infected Individuals (TERMINATED) PHASE2 NCT00170404 — TB Nutrition, Immunology and Epidemiology (COMPLETED) PHASE3 NCT00197743 — Trial of Vitamins in HIV Progression and Transmission (COMPLETED) PHASE3 NCT00311298 — Nutrition, Diabetes and Pulmonary TB/HIV (COMPLETED) PHASE3 NCT03988725 — Nonalcoholic Steatohepatitis in HIV Mono-infection: Exploring Non-invasive Methods for Diagnosis and the Therapeutic Role of Vitamin E (COMPLETED) NA NCT00421668 — A Trial of Zinc and Micronutrients in Tanzanian Children (COMPLETED) PHASE3 NCT00383669 — A Trial of Vitamins and HAART in HIV Disease Progression (COMPLETED) PHASE3 Published literature Randomized controlled trial Impact of Nutrition Education on Nutrition Knowledge, Attitudes, Practices, and Immune-Related Nutrient Intake in People Living with HIV: A Randomized Controlled Trial (Nutrients, 2026) Randomized controlled trial Vitamin A and D Deficiencies Associated With Incident Tuberculosis in HIV-Infected Patients Initiating Antiretroviral Therapy in Multinational Case-Cohort Study (Journal of acquired immune deficiency syndromes (1999), 2017) Randomized controlled trial Effect of high-dose vs standard-dose multivitamin supplementation at the initiation of HAART on HIV disease progression and mortality in Tanzania: a randomized controlled trial (JAMA, 2012) Randomized controlled trial PREDICTORS OF INCIDENT TUBERCULOSIS IN HIV-EXPOSED CHILDREN IN TANZANIA (East African medical journal, 2012) Randomized controlled trial Effect of vitamin supplements on HIV shedding in breast milk (The American journal of clinical nutrition, 2010) CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	PubChem
Calcium Natural product Systematic review Coronary Artery Calcification and Plaque Characteristics in People Livi… Systematic review Association between Immune Markers and Surrogate Markers of Cardiovascu… Systematic review Dietary supplement interactions with antiretrovirals: a systematic revi…	Nutraceutical	Approved	Emerging	19	8 trials 61 RCT View evidence Registry trials NCT02234882 — Study on Pharmacokinetics (COMPLETED) PHASE1 NCT01375010 — Vitamin D HIV Study on Postmenopausal Women (COMPLETED) PHASE1, PHASE2 NCT00392834 — Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma (COMPLETED) PHASE2 NCT01622673 — A Pharmacokinetic Study to Evaluate the Effect of Antacids on Raltegravir (MK-0518) in HIV-Infected Participants (MK-0518-247) (COMPLETED) PHASE1 NCT00801879 — Mupirocin Ointment to Eliminate Nasal Carriage of Staphylococcus Aureus in HIV Infection (COMPLETED) PHASE4 NCT00002103 — A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate (Neutrexin) With Leucovorin Protection for European Adult Patients (>= 13 Years Old) With Pneumocystis Carinii Pneumonia (COMPLETED) NA NCT04067219 — SkIn, Muscle and Bone Aging Determinants in HIV Infected-patients. (TERMINATED) NA NCT01874743 — Rosuvastatin to Decrease Residual Immune Activation in HIV Infection (UNKNOWN) PHASE2 Published literature Systematic review Coronary Artery Calcification and Plaque Characteristics in People Living With HIV: A Systematic Review and Meta-Analysis (Journal of the American Heart Association, 2021) Systematic review Association between Immune Markers and Surrogate Markers of Cardiovascular Disease in HIV Positive Patients: A Systematic Review (PloS one, 2017) Systematic review Dietary supplement interactions with antiretrovirals: a systematic review (International journal of STD & AIDS, 2017) Systematic review A systematic review of filler agents for aesthetic treatment of HIV facial lipoatrophy (FLA) (Journal of the American Academy of Dermatology, 2015) Systematic review HIV positivity, protease inhibitor exposure and subclinical atherosclerosis: a systematic review and meta-analysis of observational studies (Heart (British Cardiac Society), 2009) CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	PubChem
Vitamin D3 Natural product	Nutraceutical	Phase III	Emerging	19	8 trials 1 Cochrane 23 RCT View evidence Registry trials NCT01375010 — Vitamin D HIV Study on Postmenopausal Women (COMPLETED) PHASE1, PHASE2 NCT04067219 — SkIn, Muscle and Bone Aging Determinants in HIV Infected-patients. (TERMINATED) NA NCT01669954 — Determination of Optimum Age for DXA Screening for Osteoporosis in HIV - The Probono 1 Study (COMPLETED) NCT03930992 — Efficacy of Zoledronic Acid + Colaren vs Zoledronic Acid + Conventional Treatment for Osteoporosis in HIV+ and HIV- Men (COMPLETED) PHASE3 NCT02426840 — Calcium and High-dose Vitamin D Supplementation on Bone Mineral Density Among HIV-infected Children and Adolescents (COMPLETED) PHASE3 NCT03270709 — Effect of High-Dose Vitamin D3 in Smokers and Non-Smokers With and Without HIV (TERMINATED) PHASE1 NCT00311298 — Nutrition, Diabetes and Pulmonary TB/HIV (COMPLETED) PHASE3 NCT01702974 — Immune Reconstitution in HIV Disease (IREHIV) (COMPLETED) PHASE2 CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	PubChem
Multivitamin Natural product Randomized controlled trial Active Tuberculosis in HIV-Exposed Tanzanian Children up to 2 years of…	Nutraceutical	Phase III	Emerging	16	8 trials 2 Cochrane 2 Meta-analysis 46 Trial pubs 45 RCT View evidence Registry trials NCT01375010 — Vitamin D HIV Study on Postmenopausal Women (COMPLETED) PHASE1, PHASE2 NCT01784302 — The Effect of Antacids and Multivitamins on Raltegravir (COMPLETED) PHASE1 NCT00001077 — A Comparison of Two Caloric Supplements in the Prevention of Weight Loss in Patients With AIDS Who Take Daily Multivitamin and Mineral Supplements (COMPLETED) NCT01635153 — Effects of a Protein Calorie Supplement in HIV-infected Women With Tuberculosis (COMPLETED) NA NCT00197743 — Trial of Vitamins in HIV Progression and Transmission (COMPLETED) PHASE3 NCT00421668 — A Trial of Zinc and Micronutrients in Tanzanian Children (COMPLETED) PHASE3 NCT01171495 — Impact of Nutrition Intervention on HIV/AIDS Infected Patients (COMPLETED) PHASE3 NCT00383669 — A Trial of Vitamins and HAART in HIV Disease Progression (COMPLETED) PHASE3 Published literature Randomized controlled trial Active Tuberculosis in HIV-Exposed Tanzanian Children up to 2 years of Age: Early-Life Nutrition, Multivitamin Supplementation and Other Potential Risk Factors (Journal of tropical pediatrics, 2016) CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	—
L-Carnitine Natural product Systematic review Pharmacological treatment of painful HIV-associated sensory neuropathy:…	Amino acid	Phase III	Emerging	16	8 trials 6 RCT View evidence Registry trials NCT00002398 — Safety and Effectiveness of Giving Adefovir (Preveon) Plus Other Anti-HIV Drugs to HIV-Infected Patients Who Have Not Responded to Other Anti-HIV Drug Combinations (COMPLETED) NA NCT06845046 — A Study to Improve Skeletal Muscle in Veterans With HIV (RECRUITING) NA NCT00002219 — Safety and Effectiveness of Adding Adefovir Dipivoxil and Nelfinavir to the Anti-HIV Therapy of HIV-Infected Children (UNKNOWN) PHASE2 NCT00001082 — The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients (COMPLETED) PHASE3 NCT00000892 — A Study of Several Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Used Indinavir (COMPLETED) NA NCT00572429 — Effects of Mixed Exercise Regime and L-Carnitine Supplementation in HIV Patients on HAART (WITHDRAWN) NA NCT00000885 — Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320 (COMPLETED) PHASE2 NCT00000912 — A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients (COMPLETED) PHASE2 Published literature Systematic review Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials (PloS one, 2010) CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	PubChem
Isocomplestatin Natural product	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Chloropeptin Natural product	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Bms-387032 Natural product	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Alvocidib Natural product	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Seliciclib Natural product	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Staurosporine Natural product LEDGF/p75 Overexpression Attenuates Oxidative Stress-Induced Necrosis a…	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Lestaurtinib Natural product	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Ruxolitinib Natural product	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Nintedanib Natural product	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Fedratinib Natural product	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Doramapimod Natural product	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Enzastaurin Natural product	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Ruboxistaurin Natural product	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Tandutinib Natural product	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL

Alterations and therapeutics are aggregated from public databases (Open Targets, HPO, ChEMBL, DGIdb, and others). Natural agents are candidates from OSMF narrative reviews on opensourcemed.info/chronic-disease.html — not approved treatments. This page is for research orientation only — not medical advice.

Disease overview

Remission & chronicity

Alterations

Therapeutics

Natural Products

Part of the Open Source Medicine Foundation Network